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ATP   Adenosine triphosphate 
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cAMP   Cyclic Adenosine Monophosphat 
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CFTR   Cystic Fibrosis Transmembrane conductance Regulator 
CFU   Colony-forming Units 
COX   Cyclooxygenase 
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HPLC   High-pressure Liquid Chromatography 
ICAM-1  Intercellular Adhesion Molecule-1 
IL-1   Interleukin 1 
IL-10   Interleukin 10 
IL-6  Interleukin 6 
IL-8   Interleukin 8 
LPS   lipopolysaccharides  
LTR   Long Terminal Repeat 
MCP1   Monocyte Chemotactic Protein-1 
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NBDs   Nucleotide-Binding Domains 
NF-kB   Nuclear factor k chain in B cells 
NMR   Nuclear Magnetic Resonance 
ODN   Oligodeoxynucleotide 
PAO-1  Pseudomonas aeruginosa strain 1 
PCR   Polymerase chain reaction 
PE   Phycoerytrin 
PGs   Prostaglandins 
VII 
 
PKA   cAMP-dependent Protein Kinase 
PMN   Polymorphonuclear Neutrophil 
RANTES   Regulated on Activation Normal T Expressed and Secreted 
RD   Regulatory Domain 
RT-PCR  Retro-transcription Polymerase Chain Reaction 
TdT   Terminal Deoxynucleotidyl Transferase 
TF   Transcription Factor 
TFD   Transcription Factor Decoy 
TNF-α  Tumor Necrosis Factor-α 
 
 INTRODUCTION
  
1. CYSTIC FIBROSIS
Cystic Fibrosis (CF) 
approximately one in 2500 births among most Caucasian population
its frequency may vary in specific groups
single gene on chromosome 7 that encodes the cystic fibrosis transmembran
conductance regulator (CFTR
epithelial membranes.  
 
FIGURE 1 - Cystic fibrosis has an autosomal recessive pattern of inheritance
 
1.1 HISTORY
 
Although the entire clinical spectrum of CF was not recognized until the 1930s, 
certain aspects of CF were identified much e
Germany and Switzerland in the 1700s warned ‘’Wehe dem Kind, das beim Kuß 
auf die Stirn salzig schmekt, er ist verhext und muss bald sterbe’’ or "Woe is the 
child who tastes salty from a kiss on the brow, for he is cursed, and soon must 
die," recognizing the association between 
In the 19th century, Carl von Rokitansky
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with meconium peritonitis, a complication of meconium ileus associated with 
cystic fibrosis. Meconium ileus was first described in 1905 by Karl Landsteiner 
[1]. In 1936, Guido Fanconi published a paper describing a connection 
between celiac disease, cystic fibrosis of the pancreas, and bronchiectasis [2].                                                                                             
In 1938 Dorothy Hansine Andersen published an article, "Cystic Fibrosis of the 
Pancreas and Its Relation to Celiac Disease: a Clinical and Pathological Study," 
in the American Journal of Diseases of Children. She was the first to describe 
the characteristic cystic fibrosis of the pancreas and to correlate it with the lung 
and intestinal disease prominent in CF [3]. She also first hypothesized that CF 
was a recessive disease and first used pancreatic enzyme replacement to treat 
affected children. In 1952 Paul di Sant' Agnese discovered abnormalities 
in sweat electrolytes; a sweat test was developed and improved over the next 
decade [4].                                                                                
In 1988 the first mutation for CF, ∆F508 was discovered by Francis 
Collins, Lap-Chee Tsui and John R. Riordan on the seventh chromosome. 
Subsequent research has found over 1,000 different mutations that cause CF. 
Because mutations in the CFTR gene are typically small, classical 
genetics techniques had been unable to accurately pinpoint the mutated gene 
[5]. Using protein markers, gene-linkage studies were able to map the mutation 
to chromosome 7. Chromosome-walking and -jumping techniques were then 
used to identify and sequence the gene [6]. In 1989 Lap-Chee Tsui led a team 
of researchers at the Hospital for Sick Children in Toronto that discovered the 
gene responsible for CF in 1989. Cystic fibrosis represents the first genetic 
disorder elucidated strictly by the process of reverse genetics. 
 
1.2 CLINICAL ASPECTS 
 
Expression of the cystic fibrosis transmembrane conductance regulatory gene is 
found in areas that are lined with epithelial tissue. Some of these places include 
ciliated epithelium of high airways, the gastrointestinal tract, salivary and sweat 
glands, cervix, uterus, fallopian tubes, epididymis and the vas deferens. These 
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tissues all show some form of pathological involvement with cystic fibrosis 
[fig.2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2 - Pathological involvement in cystic fibrosis. 
 
Pulmonary disease: Lung disease is the major cause of morbidity and virtually 
all mortality: in patients with cystic fibrosis, progression of lung disease is 
insidious and patients may be relatively asymptomatic before irreversible 
changes and chronic bacterial colonization occur. The first detectable evidence 
of lung disease in patients with cystic fibrosis is infection and inflammation in 
bronchoalveolar lavage fluid (BLF), denoted by elevated counts of interleukin-8 
and neutrophils and the presense of microorganisms [7, 8]. Overall, 
Pseudomonas aeruginosa (PAO) is the most common isolate, followed by 
Haemophilus influenza and Staphylococcus aureus: chronic colonization with P. 
aeruginosa  is associated with a more rapid decline in lung function [9,10]. 
An exaggerated, sustained and axtended inflammatory response to bacterial 
and viral pathogens – characterized by neutrophil dominated airway 
inflammation – is the feature of lung disease in cystic fibrosis. Inflammation is 
present even in clinically stable patients with some lung disease and in young 
infants diagnosed by neonatal screening. Quantification of airway inflammation 
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is necessary to monitor its evolution over time and the effect of anti-
inflammatory treatment. This monitoring remains a difficult task, since reliable 
non invasive markers of airway inflammation are not available. 
 
Gastrointestinal, liver and pancreatic disease: Prior to prenatal and newborn 
screening, cystic fibrosis was often diagnosed when a newborn infant failed to 
pass feces (meconium). Meconium may completely block the intestines and 
cause serious illness. This condition, called meconium ileus, occurs in 10% of 
newborns with CF [11]. In addition, protrusion of internal rectal membranes 
(rectal prolapse) is more common in CF because of increased fecal volume, 
malnutrition, and increased intra–abdominal pressure due to coughing [12]. The 
thick mucus seen in the lungs has a counterpart in thickened secretions from 
the pancreas, an organ responsible for providing digestive juices that help break 
down food. These secretions block the movement of the digestive enzymes into 
the duodenum and result in irreversible damage to the pancreas, often with 
painful inflammation (pancreatitis) [13]. The lack of digestive enzymes leads to 
difficulty absorbing nutrients with their subsequent excretion in the feces, a 
disorder known as malabsorption. Malabsorption leads to malnutrition and poor 
growth and development because of caloric loss. Individuals with CF also have 
difficulties absorbing the fat-soluble vitamins A, D, E, and K. In addition to the 
pancreas problems, CF patients experience more heartburn, intestinal blockage 
by intussusception, and constipation [14]. Older CF patients may also 
develop distal intestinal obstruction syndrome when thickened feces cause 
intestinal blockage [15]. Thickened secretions also may cause liver problems in 
patients with CF. Bile secreted by the liver to aid in digestion may block the bile 
ducts, leading to liver damage. Over time, this can lead to cirrhosis, in which the 
liver fails to rid the blood of toxins and does not produce important proteins such 
as those responsible for blood clotting [16-17].  
Endocrine disease: the pancreas contains the islets of Langerhans, which are 
responsible for making insulin, a hormone that helps regulate blood glucose. 
Damage of the pancreas can lead to loss of the isletcells, leading to a type of 
diabetes that is unique to those with the disease [18]. This Cystic Fibrosis 
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Related Diabetes (CFRD) shares characteristics that can be found in Type 
1 and Type 2 diabetics and is one of the principal non-pulmonary complications 
of CF [19].  
 
Osteoporosis: Vitamin D is involved in calcium and phosphorus regulation. 
Poor uptake of vitamin D from the diet because of malabsorption can lead to the 
bone disease osteoporosis in which weakened bones are more susceptible 
to fractures [20]. In addition, CF patients often develop clubbing of their fingers 
and toes due to the effects of chronic illness and low oxygen in their tissues. 
 
Infertility: Infertility affects both men and women. At least 97 percent of men 
with cystic fibrosis are infertile but are not sterile and can have children with 
assisted reproductive techniques [21]. These men make normal sperm but are 
missing the tube (vas deferens), which connects the testes to the ejaculatory 
ducts of the penis [22]. Many men found to have congenital absence of the vas 
deferens during evaluation for infertility have a mild, previously undiagnosed 
form of CF [23]. Some women have fertility difficulties due to thickened cervical 
mucus or malnutrition. In severe cases, malnutrition disrupts ovulation and 
causes amenorrhea [24].  
 
1.3 DIAGNOSIS AND MONITORING 
 
Cystic fibrosis may be diagnosed by many different categories of testing 
including those such as, newborn screening, sweat testing, or genetic testing. 
The newborn screen initially measures for raised blood concentration 
of immunoreactive trypsinogen [25]. Infants with an abnormal newborn screen 
need a sweat test in order to confirm the CF diagnosis. Trypsinogen levels can 
be increased in individuals who have a single mutated copy of the CFTR gene 
(carriers) or, in rare instances, even in individuals with two normal copies of the 
CFTR gene. Due to these false positives, CF screening in newborns is 
somewhat controversial [26-27]. Therefore, most individuals are diagnosed after 
symptoms prompt an evaluation for cystic fibrosis. The most commonly used 
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form of testing is the sweat test. Sweat-testing involves application of a 
medication that stimulates sweating (pilocarpine) to one electrode of an 
apparatus and running electric current to a separate electrode on the skin. This 
process, called iontophoresis, causes sweating; the sweat is then collected on 
filter paper or in a capillary tube and analyzed for abnormal amounts 
of sodium and chloride. CF patients have increased amounts of sodium and 
chloride in their sweat [fig.3]. CF can also be diagnosed by identification of 
mutations in the CFTR gene [28]. 
 
 
 
FIGURE 3 - Diagram of a sweat gland, showing paths taken by chloride ions (arrows) during 
secretion. In both normal and CF sweat glands in the dermis, chloride is present in secretions at 
a concentration of 105 mEq, equaling that in serum (“isotonic”). (Top) In the normal sweat 
gland, chloride is absorbed out of the sweat in a CFTR-dependent manner as the sweat travels 
from the gland to the skin surface. As a result, the chloride concentration in normal sweat is 
below that in serum (“hypotonic”), with <40 mEq considered normal and <20 mEq being typical. 
(Bottom) In the CF sweat gland, chloride absorption is hindered by defective CFTR function. As 
a result, sweat which reaches the skin surface has higher than normal chloride concentrations 
(>60 mEq). 
 
A multitude of tests are used to identify complications of CF and to monitor 
disease progression. X-rays and CAT scans are used to examine the lungs for 
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signs of damage or infection. The examination of the sputum is required to 
isolate organisms which may be causing an infection or colonising the lower 
respiratory tract so that effective antimicrobial therapy can be provided. Culture 
for organisms such as Burkholderia cepacia (previously Pseudomonas)  is 
required for candidates of lung transplantation as persisant bacterial 
colonisation reduces the chances of survival.  
Pulmonary function tests measure how well the lungs are functioning, and are 
used to measure the need for and response to antibiotic therapy. Blood 
tests can identify liver abnormalities, vitamin deficiencies, and the onset of 
diabetes. DEXA scans can screen for osteoporosis and testing for fecal 
elastase can help diagnose insufficient digestive enzymes. 
 
1.4 PRENATAL DIAGNOSIS 
 
Couples who are pregnant or who are planning a pregnancy can themselves be 
tested for CFTR gene mutations to determine the degree of risk that their child 
will be born with cystic fibrosis. Testing is typically performed first on one or 
both parents and, if the risk of CF is found to be high, testing on the fetus can 
then be performed. Because development of CF in the fetus requires each 
parent to pass on a mutated copy of the CFTR gene and because CF testing is 
expensive, testing is often performed on just one parent initially. If that parent is 
found to be a carrier of a CFTR gene mutation, the other parent is then tested to 
calculate the risk that their children will have CF. CF can result from more than 
a thousand different mutations and it is not possible to test for each one. 
Testing analyzes the blood for the most common mutations such as ∆F508 - 
most commercially available tests look for 32 or fewer different mutations. If a 
family has a known uncommon mutation, specific screening for that mutation 
can be performed. Because not all known mutations are found on current tests, 
a negative screen does not guarantee that a child will not have CF [29]. In 
addition, because the mutations tested are necessarily those most common in 
the highest risk groups, testing in lower risk ethnicities is less successful 
because the mutations commonly seen in these groups are less common in the 
8 
 
general population. Couples who are at high risk for having a child with CF will 
often opt to perform further testing before or during pregnancy.  In vitro 
fertilization with preimplantation genetic diagnosis offers the possibility to 
examine the embryo prior to its placement into the uterus. The test, performed 
three days after fertilization, looks for the presence of abnormal CF genes. If 
two mutated CFTR genes are identified, the embryo is not used for embryo 
transfer and an embryo with at least one normal gene is implanted. During 
pregnancy, testing can be performed on the placenta (chorionic villus sampling) 
or the fluid around the fetus (amniocentesis).  
  
1.5 THERAPY 
 
Although no definite cure has been discovered for cystic fibrosis as of yet, many 
treatments have been developed to improve the quality of life for those who 
suffer from this disorder. Since CF causes a build-up of mucus in the lung 
tissue, the respiratory diseases which result are often the actual cause of death, 
not CF itself. 
 
 1.5.1 ANTI-INFLAMMATORY THERAPY 
Inflammation plays a major role in the pathophysiology of lung disease in CF. 
This respose is probably triggered primarily as a reaction to the inability of the 
affected lung to resist the invasion of the most common bacterial pathogens 
seen in this disease. 
Anti-inflammatoty therapy can be provided in various forms: these include the 
use of oral corticosteroids which are potentially highly effective but which carry 
with them the risk of long-term systemic side effects. 
Inhaled corticosteroids also have considerable potential because of their local 
action within the lung. Their potential therapeutic disadvantage is the difficulty of 
penetrating the viscid mucus which lines the airway in CF patients particularly 
as the disease progresses. 
Other anti-inflammatory agents such as ibuprofen have considerable potential 
and have been the subject of various studies over the years. 
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More recently macrolides have come forward as potent anti-inflammatory 
agents and are beginning to have an established place in the therapeutic 
regimen for patients with long-term Pseudomonas aeruginosa infection. Other 
agents which have been used include immunoglobulins and dornase alpha 
(DNase) that may have an anti-inflammatory role as well as being mucolytic.  
 
1.5.2 CHEMOTERAPY 
Many CF patients are on one or more antibiotic at all times, even when they are 
considered healthy, in order to prophylacticly suppress infection. Antibiotics are 
absolutely necessary whenever pneumonia is suspected or a lung function 
decline has been noticeable, and are usually chosen based on the results of a 
sputum analysis and the patient's past response. Many bacteria common in 
cystic fibrosis are resistant to multiple antibiotics and require weeks of treatment 
with Intravenous antibiotics such as vancomycin, tobramycin, meropenem, 
ciprofloxacin and piperacillin. This prolonged therapy often necessitates 
hospitalization and insertion of a more permanent IV such as a peripherally 
inserted central catheter (PICC) line or Port-a-Cath. Inhaled therapy with 
antibiotics such as tobramycin and colistin is often given for months at a time in 
order to improve lung function by impeding the growth of colonized bacteria [30, 
31]. Inhaled antibiotic therapy with aztreonam is also being developed and 
clinical trials are underway [32]. Oral antibiotics such as ciprofloxacin 
or azithromycin are given to help prevent infection or to control ongoing 
infection [33]. Several of the antibiotics commonly used to treat CF patients, 
such as tobramycin and vancomycin, can cause hearing loss, damage to 
the balance system in the inner ear or kidney problems with long-term use. In 
order to prevent these side effects, the amount of antibiotics in the blood are 
routinely measured and adjusted accordingly. 
 
 1.5.3 OTHER METHODS TO TREAT LUNG DISEASE 
Several mechanical techniques are used to dislodge sputum and encourage its 
expectoration. In the hospital setting, chest physiotherapy (CPT) is utilized; a 
respiratory therapist percusses an individual's chest with his or her hands 
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several times a day, to loosen up secretions. Devices that recreate this 
percussive therapy include the ThAIRapy Vest and the intra-pulmonary 
percussive ventilator (IPV).         
Newer methods such as biphasic cuirass ventilation (BCV), and associated 
clearance mode available in such devices, integrate a cough assistance phase, 
as well as a vibration phase for dislodging secretions. Biphasic Cuirass 
Ventilation is also shown to provide a bridge to transplantation.These are 
portable and adapted for home use [34].                
Physiotherapy is essential to help manage an individual’s chest on a long term 
basis, and can also teach techniques for the older child and teenager to 
manage themselves at home. Aerobic exercise is of great benefit to people with 
cystic fibrosis. Not only does exercise increase sputum clearance but it also 
improves cardiovascular and overall health.Aerosolized medications that help 
loosen secretions include dornase alfa and hypertonic saline [35]. Dornase is 
a recombinant human deoxyribonuclease, which breaks down DNA in the 
sputum, thus decreasing  its viscosity [36]. N-Acetylcysteine may also decrease 
sputum viscosity, but research and experience have shown its benefits to be 
minimal.  Albuterol and ipratropium bromide are inhaled to increase the size of 
the small airways by relaxing the surrounding muscles.          
As lung disease worsens, mechanical breathing support may become 
necessary. Individuals with CF may need to wear special masks at night that 
help push air into their lungs. These machines, known as bilevel positive airway 
pressure (BiPAP) ventilators, help prevent low blood oxygen levels during 
sleep. BiPAP may also be used during physical therapy to improve sputum 
clearance [37]. During severe illness, a tube may be placed in the throat (a 
procedure known as a tracheostomy) to enable breathing supported by 
a ventilator. 
 
1.5.4 TREATMENT OF OTHER ASPECTS 
Newborns with meconium ileus (bowel obstruction) typically require surgery, 
whereas adults with distal intestinal obstruction syndrome typically do not. 
Treatment of pancreatic insufficiency by replacement of missing digestive 
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enzymes allows the duodenum to properly absorb nutrients and vitamins that 
would otherwise be lost in the feces. Even so, most individuals with CF are 
advised take additional amounts of vitamins A, D, E, and K and eat high-calorie 
meals. So far, no large-scale research involving the incidence 
of atherosclerosis and coronary heart disease in adults with cystic fibrosis has 
been conducted. This is likely due to the fact that the vast majority of people 
with cystic fibrosis do not live long enough to develop clinically significant 
atherosclerosis or coronary heart disease.  
Diabetes is the most common non-pulmonary complication of CF. It mixes 
features of type 1 and type 2 diabetes, and is recognized as a distinct entity, 
cystic fibrosis-related diabetes (CFRD) [38,39]. While oral anti-diabetic 
drugs are sometimes used, the only recommended treatment is the use 
of insulin injections or an insulin pump [40], and, unlike in type 1 and 2 diabetes, 
dietary restrictions are not recommended [38].  
Development of osteoporosis can be prevented by increased intake of vitamin D 
and calcium, and can be treated by bisphosphonates, although adverse 
effects can be an issue [41]. Poor growth may be avoided by insertion of 
a feeding tube for increasing calories through supplemental feeds or by 
administration of injected growth hormone [42].  
Sinus infections are treated by prolonged courses of antibiotics. The 
development of nasal polyps or other chronic changes within the nasal 
passages may severely limit airflow through the nose, and over time reduce the 
patient's sense of smell. Sinus surgery is often used to alleviate nasal 
obstruction and to limit further infections. Nasal steroids such as fluticasone are 
used to decrease nasal inflammation [43]. Female infertility may be overcome 
by assisted reproduction technology, particularly embryo transfer techniques. 
Male infertility may be overcome with intracytoplasmic sperm injection 
[44]. Third party reproduction is also a possibility for women with CF. 
 
1.5.5 GENE THERAPY  
Cystic fibrosis should be an ideal candidate for gene therapy, for four main 
reasons: (1) it is a single gene defect; (2) it is a recessive condition, with 
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heterozygotes being phenotypically normal (suggesting gene dosage effects are 
not critical); (3) the main pathology is in the lung, which is accessible for 
treatment; and (4) it is a progressive disease with a virtually normal phenotype 
at birth, offering a therapeutic window.  
It has been suggested that only 5–10% of normal CFTR function is required to 
reverse the chloride channel defect [45], although it is not clear whether this has 
to be achieved in the majority of the airway epithelial cells, or whether a minority 
of cells expressing much higher levels would suffice. In clinical trials to date, two 
main vector systems have been harnessed to deliver the CFTR cDNA with 
appropriate promoter into host cells [46,47]. First, viral vectors with the CFTR 
cDNA incorporated into the viral genome exploit the efficiency of viruses to 
enter host cells and achieve relatively high levels of gene expression. Secondly, 
cationic liposomes mixed with plasmid DNA encoding CFTR enhance the 
transport of the DNA into host cells. Although cationic liposomes seem to 
generate a lower immune response than current viral vector systems, the levels 
of CFTR expression using this delivery system have been relatively poor.  
The ideal vector system would have the following characteristics: (1) an 
adequate carrying capacity; (2) to be undetectable by the immune system; (3) to 
be non-inflammatory; (4) to be safe to the patients with pre-existing lung 
inflammation; (5) to have an efficiency sufficient to correct the cystic fibrosis 
phenotype; and (6) to have long duration of expression and/or the ability to be 
safely re-administered.  
In-vivo gene therapy trials in patients with cystic fibrosis have been done with 
viral vectors and cationic lipids, [48, 49] however, long-term effects were not 
achieved. Repeat administration of adenovirus vectors reduces efficacy of 
transfection because of formation of specific antibodies, whereas lipids might 
not specifically target CFTR-expressing cells. Therefore, although much 
progress has been made in gene therapy, it is presently not a treatment option 
for patients with cystic fibrosis. 
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 1.5.6 STEM CELLS 
CF is a potential model disease for stem cell therapy because of the continuing 
lung inflammation and infection leading to damage, which could promote 
engraftment of stem cells. It is likely that infants and children with CF would be 
the best candidates for this sort of therapy, when they have faster cell turnover 
and before they have established lung damage: the ultimate therapy will be 
gene therapy to CF babies by utilizing their own stored umbilical cord blood 
stem cells [50]. 
Nevertheless, experiments to elucidate possible lung stem cell candidates are 
difficult because of the slow turnover of such cells, and therefore most animal 
studies use an injury model which promotes cell turnover. Moreover, basic 
questions remain unanswered. It is unknown which cell type should be targeted; 
current topical therapy targets the abundant surface epithelium, but it is the 
submucosal glands which expresses the highest CFTR in the lung. 
 
1.5.7 LUNG TRANSPLANTATION 
Double lung or heart-lung transplantation is a treatment option for patients with 
cystic fibrosis and end-stage lung disease. Overall survival of lung-transplant 
patients is poorer than for other organ transplantation, with 3-year survival of 
about 60% in patients with cystic fibrosis [51]. Generally, survival is better for 
adults than for children [52], but some centres have reported a survival benefit 
in children [53]. 
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2. CFTR: CYSTIC FIBROSIS TRANSMEMBRANE 
CONDUCTANCE REGULATOR 
 
2.1 CFTR PROTEIN  
 
Cystic fibrosis transmembrane conductance regulator (CFTR) is a 
phosphorylation-dependent epithelial Cl- channel. It is located primarily in the 
apical membrane, where it provides a pathway for Cl- movement across 
epithelia and regulates the rate of Cl- flow. Thus CFTR is central in determining 
transepithelial salt transport, fluid flow, and ion concentrations. In the intestine, 
pancreas, and sweat gland secretory coil, CFTR plays a key role in fluid and 
electrolyte secretion, and in sweat gland duct and airway epithelia, it 
participates in fluid and electrolyte absorption.  
CFTR can also regulate other membrane proteins [54]. The most thoroughly 
documented regulatory role for CFTR is its negative regulation of the amiloride-
sensitive epithelial Na+ channel (ENaC). CFTR decreases ENaC's open 
probability (Po) and reverses its usual increases to elevations of [cAMP]i [55]. 
When CFTR function is lost, the Na+ conductance is markedly increased in CF 
human airways [56] and CF mouse nasal epithelia [57], but apparently not in 
human sweat ducts [58]. CFTR's channel and regulatory [59] functions require 
that it has to be phosphorylated by various kinases, especially cAMP-dependent 
protein kinase (PKA).  
To summarize, CFTR is an anion channel and a channel regulator that plays 
multiple roles in epithelial transport. Although other functions have been 
proposed for CFTR, most present hypotheses of CF disease emphasize 
CFTR's roles in ion transport [fig.4]. 
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FIGURE 4 - CFTR's multiple roles in fluid and electrolyte transport. (a) Salt absorption. In the 
sweat duct, high apical conductance for Na+ [1] and Cl– [2] and relatively low water conductance 
allows salt to be reabsorbed in excess of water (hypertonic absorption) leaving a hypotonic 
luminal fluid. In the sweat duct CFTR is the only available anion conductance pathway, and 
when it is lost in CF the lumen quickly becomes highly electronegative and transport virtually 
ceases, resulting in high (similar to plasma) luminal salt. (b) Fluid absorption. In epithelia with 
high water permeability [3] relative to electrolyte permeability water will absorbed osmotically 
with salt to decrease the volume of luminal fluid. If no other osmolytes or forces are present, the 
salt concentration will remain unchanged. If water-retaining forces are present, permeant 
electrolytes can be reduced preferentially. The consequences of eliminating CFTR depend on 
the magnitude of such forces, the relative magnitude of alternate pathways for transepithelial 
anion flow [4], and how CFTR affects other ion channels. The high salt and low volume 
hypotheses differ on each of these points. (c) Anion-mediated fluid secretion. Secreting 
epithelia lack a significant apical Na+ conductance. Basolateral transporters such as NKCC 
move Cl– uphill into the cell; it then flows passively into the lumen via CFTR [5], K+ exits 
basolaterally, Na+ flows paracellularly [7] and water follows transcellularly [6]. Elimination of 
CFTR eliminates secretion [60]. 
 
CFTR is a member of the ATP-binding cassette (ABC) transporter family, and it 
contains the features characteristic of this family: two nucleotide binding 
domains (NBDs) and two six-membrane-spanning domains (MSDs) [59] [fig.5].  
Moreover CFTR also contains the R domain (RD), a unique sequence not found 
in other ABC transporters or any other proteins. The R domain serves as the 
major physiologic regulator of the CFTR Cl- channel. When cAMP level 
increase, cAMP-dependent protein kinase (PKA) phosphorylates the multiple 
serine residues within the R domain allowing ATP to open the channel.  
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PKA is the primary kinase that phosphorylates CFTR, although protein kinase 
C, cGMP-dependent protein kinase, and tyrosine phosphorylation can also 
stimulate channel activity [61]. 
 
 
FUGURE 5 -  Model showing proposed domain structure of cystic fibrosis transmembrane 
conductance regulator (CFTR). MSD, membrane-spanning domain; NBD, nucleotide-binding 
domain; R, regulatory domain; PKA, cAMP-dependent protein kinase. 
 
Once the R domain is phosphorylated, channel gating is regulated by a cycle of 
ATP hydrolysis at the NBDs. Finally, protein phosphatases dephosphorylate the 
R domain and return the channel to its quiescent state. At the moment, how 
phosphorylation activates the channel is not well understood. Some models 
propose that the R domain prevents the channel from opening and that 
phosphorylation relieves this inhibition. Other models suggest that 
phosphorylation of the R domain stimulates activity.       
These channels have several distinguishing characteristics: 
 
• They have a small single-channel conductance (6–10 pS).  
• The current-voltage (I-V) relationship is linear.  
• They are selective for anions over cations.  
• The anion permeability sequence is Br- ≥ Cl- > I-.  
• They show time- and voltage-independent gating behavior.  
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• Their activity is regulated by cAMP-dependent phosphorylation and by 
intracellular nucleotides.  
 
These features are conferred on CFTR Cl- channels by the function of the 
MSDs, the NBDs, and the R domain. 
 
 
 
FIGURE 6 - CFTR structure. 
 
In the proposed transmembrane topology [fig.6], which is supported by 
experimental evidence [62-64], 77% of the protein is in the cytoplasm, 19% in 
membrane spanning segments, and 4% in extracellular loops. 
The minimum channel diameter was inferred to be 5.3 Å based on the size of 
the largest permeant anion [65]. Further studies using patches with larger 
numbers of channels showed that anions as large as lactobionate (10–13 Å in 
diameter) were slightly permeable. Thus, at least transiently, the diameter of the 
channel must be 10–13 Å [66]. In the presence of cytoplasmic ATP the large 
anions were only permeable from the cytoplasmic side [66]. The molecular  
basis for asymmetric permeation by large anions is unknown. 
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2.1.1 FROM CFTR TO LUNG DISEASE 
The vexing problem of explaining CF lung disease using known properties of 
CFTR has recently been energized by two innovative but sharply different 
hypotheses [fig.7]. Interestingly, both hypotheses consider CFTR's role in salt 
absorption to be primary. 
 
 
FIGURE 7 - Two hypotheses of how airway surface liquid (ASL) differs in healthy and CF lungs. 
(a) The high salt hypothesis [67,68] postulates that normal ASL has low levels of salt as a result 
of salt absorption in excess of water (A1, left). Even though the epithelium is water permeable, 
salt is retained in thin surface films by some combination of surface tension [69] and 
impermeant osmolytes [68]. In CF (A2 right), salt is poorly absorbed resulting in excessively 
salty ASL that disrupts natural mucosal antibiotics. Key features of the high salt model are: the 
lack of an appreciable shunt Cl– conductance, central importance of CFTR's channel role, no 
specific role for inhibition of ENaC by CFTR, and a switch from isotonic volume absorption to 
hypertonic salt absorption as the surface layer thins and traps residual water. (b) The low 
volume hypothesis [73] postulates that normal ASL (B1 left) has salt levels approximately equal 
to plasma. In CF (B2 right), the removal of CFTR's inhibition of ENaC results in abnormally 
elevated isotonic fluid absorption which depletes the ASL and leads to reduced mucociliary 
clearance. Key features of the low volume model are the parallel pathway for Cl–via shunt 
pathway(s) and inhibition of ENaC via CFTR. 
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The high salt hypothesis [67-68] emphasizes CFTR's function as an anion 
channel. According to this hypothesis, missing or defective CFTR causes 
reduced transepithelial Cl- conductance, and by analogy with the sweat duct 
[70-71] this allows salt levels in the apical surface liquid (ASL) to remain at 
levels similar to those in plasma [fig.7]. The high salt in the ASL interferes with 
natural antibiotics such as defensins [72] and lysozyme.             
In marked contrast, the low volume hypothesis [73] is based on CFTR's function 
as a regulator of other channels - in this case ENaC. According to this 
hypothesis, both normal and CF ASL have plasma-like levels of salt. CFTR 
mutations eliminate CFTR's inhibition of ENaC, and because there are 
significant shunt pathways for Cl– in the airways, increased Na+ transport drives 
increased absorption of Cl– and water. Thus CF airways display accelerated 
isotonic fluid absorption that depletes ASL volume and dehydrates mucus, 
leading to obstruction and infection [74]. 
 
 2.2 CFTR GENE 
 
The gene responsible for CFTR was identified to reside on the long arm of 
chromosome 7 (7q.31.2) and subsequently isolated by positional cloning in 
1989 [3-5,75] [fig.8].  
 
 
FIGURE 8 - The location of the CFTR gene on chromosome 7. 
20 
 
Availability of the gene sequence and direct mutation analysis were turning 
points in the history of CF and opened a new chapter of molecular and cellular 
studies in CF research.  
The gene, named the CF transmembrane conductance regulator (CFTR), 
consists of a TATA-less promoter and 27 exons spanning about 215 kb of 
genomic sequence [fig.9-a] [76]. The CFTR gene encodes a 170 kDa (1480 
amino acids) transmembrane protein with a symmetrical, multi-domain 
structure, consisting of two membrane-spanning domains (MSD1, MSD2), two 
nucleotide-binding domains (NBD1, NBD2) and a central, highly charged 
regulatory domain (RD) with multiple phosphorylation consensus sites [fig.9b-c] 
[5]. The principal function of CFTR is that of cAMP-regulated chloride transport 
at the apical membranes of epithelial cells but has also been implicated in many 
other processes such as regulation of other ion channels, membrane trafficking, 
pH regulation and apoptosis. 
 
 
 
FIGURE 9 - Schematic diagram of the CFTR gene. (a) Structure of the CFTR gene consisting of 
promoter region (P) and 27 exons. The size of the introns is based on the sequences of 
genomic BAC clones 068P20 and 133K23 (submitted to GenBank by Washington University). 
(b) CFTR polypeptide with predicted domains (highlighted). (c) Topology of the CFTR protein 
relative to the cytoplasmic membrane and position of the most common mutation, ∆F508. MSD1 
and MSD2 = Membrane spanning domains 1 and 2; NBD1 and NBD2 = nucleotide-binding 
domains 1 and 2; R = regulatory domain. Box: Deletion of 3 nucleotides, CTT (underlined), and 
subsequent loss of phenylalanine (underlined) at position 508 of the CFTR protein. 
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2.3 CFTR MUTATIONS  
 
The first, and as it turned out, the most common CFTR defect identified among  
Caucasians was the ∆F508 mutation [fig.11], a 3-bp deletion in exon 10 causing 
a loss of phenylalanine at the amino acid position 508 of the protein product [fig. 
9c][75]. Presently, 10 years after the discovery of the CFTR gene, more than 
850 different alleles have been reported as proven or putative disease causing 
mutations (CFGAC website: http://www.genet.sickkids.on.ca/cftr/).  
 
Feature How may it affect a phenotype? 
A - Type of mutation Mutations that are predicted to prevent CFTR biosynthesis or produce grossly changed, unstable or 
nonfunctional proteins tend to have severe phenotypic consequences (type: nonsense, frameshift, splice, 
large in-frame deletion or insertion); effects of mutations that cause minor, local changes in the protein 
may range from mild to severe depending on other factors such as its molecular mechanism, amino acid 
change or location (type: missense, small inframe deletion or insertion) 
 
 
 
B – Molecular mechanism Immediate consequence of the mutation for CFTR biosynthesis, processing, trafficking to 
the membrane, stability and function (classes of mutations); the mechanisms of mutations 
are evaluated empirically on the molecular and cellular levels 
C -  Position in the gene 
(protein) 
Applies particularly to minor, local changes (missense); mutations in structurally or functionally 
critical regions of the protein tend to correlate with more severe phenotypes when compared 
with mutations in less important regions; amino acid substitutions in highly conserved regions of  
CFTR protein may also have more severe phenotypic consequences than mutations from 
 unconserved regions 
 
D -  Net molecular effect The net amount of the functional CFTR present in the apical membrane of secretory epithelial 
cells, irrespective of type mutation or its mechanism; production of even a small amount of functional 
CFTR may be sufficient to prevent a severe disease (class IV and V mutations) 
E  - Intragenic modulators 
(complex alleles) 
In some cases, a second change in the same allele may modulate the phenotypic effect of the 
primary mutation; for example, the missense mutation R117H associated with the 5T variant 
in the T-tract of the acceptor splice site of intron 8 is typically associated with the pancreatic sufficient 
form of CF but only with infertility (males) or asymptomatic presentation (females) when on the 7T 
background 
 
F -  Impact of second 
mutation 
As a recessive disease, CF requires the presence of mutations in each allele; therefore, the 
type and molecular consequences of the second mutation in the genotype may be critical for 
the clinical outcome; for example, a severe allele is associated with PI only if the second mutation is 
severe; conversely, one mild mutation is sufficient to preserve pancreatic function, irrespective of the type 
of the second allele 
 
 
G - Site of 
expression/organ 
pathophysiology/ 
secondary modulation 
A phenotypic impact of a mutation also depends on where the mutation is expressed and organ-specific 
pathophysiology; in some organs like the pancreas, a CFTR genotype closely correlates with the severity 
of its phenotype (PI vs. PS); in lungs, with complex pathophysiology, the primary effect of a particular 
genotype may be considerably modulated by secondary genetic factors and environment 
 
Table 1 - What determines a phenotypic effect of a mutation? 
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All types of mutations are represented (missense, frameshift, nonsense, splice, 
small and large in-frame deletions or insertions), and are distributed throughout 
the entire gene [fig.10]. The potential of a mutation to contribute to the severity 
of a CF phenotype depends on multiple factors [table 1, A-G].  
 
 
FIGURE 10 - Over 550 different mutations have been characterised in the CF gene CFTR. 
 
Firstly, it is inherent to a characteristic mutation profile on the molecular and 
cellular levels as determined by its type (A), class (B) and position in the gene 
(C). Secondly, it depends on the other intragenic factors (E) such as a presence 
of other changes within the gene (complex allele), influence of a second 
mutation in the genotype (F) and secondary genetic and environmental factors 
associated with a pathogenesis of the affected organ (G). Due to a large 
number of disease-contributing mutations affecting the function of the CFTR 
gene to a different degree, a CFTR genotype has high potential as a primary 
source of phenotypic variability in CF. 
 
2.3.1 MOLECULAR MECHANISMS OF CFTR MUTATIONS 
 
Various mutations can be grouped into different classes [fig.11] based on their 
known or predicted molecular mechanisms of dysfunction and functional 
consequences for the CFTR protein.  
Although schematic, such classification can often be a good indication of a 
mutation’s severity and provides a rationale for their phenotypic consequences 
[table 1, B, D]. 
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FIGURE 11 – Six classes of CFTR Mutations. 
 
• CLASS I: DEFECTIVE PROTEIN SYNTHESIS  
Net Effect: No CFTR Protein at the Apical Membrane. Mutations that belong to 
this category are associated with lack of biosynthesis or defective biosynthesis 
producing abnormal protein 
variants (truncation, deletion, etc.). These are usually nonsense, frameshift, 
RNA splice-type mutations or missense mutations changing translation initiation 
codon (methionine at position 1). Due to their grossly altered structure, they 
tend to be unstable and efficiently cleared from the cell. In effect, virtually no 
functional CFTR is present at the apical membrane of the epithelial cells and 
as a consequence phenotypic effects of class I mutations tend to be severe. 
 
• CLASS II: ABNORMAL PROCESSING AND TRAFFICKING  
Net Effect: No CFTR Protein at the Apical Membrane. Many CFTR gene 
variants expressed in various heterologous systems fail to be properly 
Classe 1: mancata sintesi
Classe 2: difetto di maturazione
Classe 3: difetto di attivazione
Classe 4: difetto di conduttanza
Classe 5: difetto di sintesi
Classe 6: difetto di regolazione
nucleo
Class I – defective production 
Class II – defective processing 
Cla s III – efective regulation 
Class IV – defective c uctance 
Class V – defective amount 
Class VI – decreased stability 
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processed to a mature glycosylated form and transported to the apical 
membrane. Because of their absence in the membrane, these mutant CFTR 
variants are typically associated with severe CF phenotypes. Interestingly, 
some of the class II mutations – such as the most common ∆F508 mutation 
[fig.12] – if correctly processed, possess residual Cl channel activity and may 
lead to a sustained normal or only mildly affected phenotype. For this reason, 
mutations in this group – in particular the common ∆F508 deletion – are the 
targets of potential therapies, aimed at correcting the processing and delivery of 
a mutated CFTR protein to the apical membrane.  
 
 
FIGURE 12 - The ∆F508 deletion is the most common cause of cystic fibrosis. 
 
Recent studies of endogenous CFTR expression in CF-relevant epithelial 
tissues from patients homozygous for the ∆F508 mutation demonstrated 
however that immunolocalized distribution of CFTR in certain tissues 
(respiratory and intestinal) is indistinguishable from that observed in the 
corresponding wild-type cells [77]. The ∆F508 CFTR protein was absent only in 
sweat gland ducts of those patients. It is still possible that the ∆F508 CFTR is 
compartmentalized in vesicles in close proximity to the cell membrane and 
therefore gives the appearance of being embedded in the membrane. It should 
be noted, however, that the efficiency of processing and trafficking of the ∆F508 
CFTR protein may vary conside ably between different epithelial cells. 
Therefore, different intracellular conditions may result in variable severity of 
tissue- or organ-specific pathophysiology. 
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• CLASS III: DEFECTIVE REGULATION  
Net Effect: Normal Amount of Nonfunctional CFTR at the Apical Membrane. 
Mutations in this class affect the regulation of CFTR function by preventing ATP 
binding and hydrolysis at the nucleotide binding domains (NBD1; NBD2) 
required for the channel activation. Alterations within NBD1 (such as missense 
mutation G551D) may also affect CFTR regulation of other channels such as 
the outwardly rectifying chloride channel [78] or ROMK2 potassium channel 
[79]. This is an example of a mutation mechanism which affects some 
regulatory functions of CFTR in addition to its chloride transporting function. 
 
• CLASS IV: DECREASED CONDUCTANCE  
Net Effect: Normal Amount of CFTR with Some Residual Function at the Apical 
Membrane. Several mutations (R117H, R334W, R347P) were shown to affect 
the properties of CFTR single-channel conductance [80]. Interestingly, these 
mutations are located within MSD1 which is implicated in forming the pore of 
the channel [81] and the corresponding CFTR variants retain residual function. 
Alleles in this class are typically associated with a milder pancreatic phenotype: 
this includes patients with pancreatic sufficency (PS). 
 
• CLASS V: REDUCED SYNTHESIS/TRAFFICKING  
Net Effect: Reduced Amount of Functional CFTR at the Apical Membrane. 
Various mutations may be associated with reduced biosynthesis of fully active 
CFTR due to partially aberrant splicing (3849+10kbC→T) [82], promoter 
mutations or inefficient trafficking (A455E) [83, 84]. These mutations result in 
reduced expression of functional CFTR channels in the apical membrane. Class 
V mutations are associated with a milder CF phenotype. 
 
• CLASS VI: DECREASED STABILITY  
Net Effect: Functional but Unstable CFTR Present at the Apical Membrane. 
According to a new study, truncation of the C-terminus of CFTR leads to the 
marked instability of an otherwise fully processed and functional variant. These 
are usually nonsense or frameshift mutations (Q1412X, 4326delTC, 4279insA) 
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causing a 70- to 100-bp truncation of the Cterminusof the CFTR [85] and 
associated with severe CF presentation. The above classification categorizes 
CFTR mutations according to their molecular mechanisms and consequences 
for different aspects of CFTR biogenesis, metabolism and function but it does 
not exclude an association of a mutation with more than one mechanism (e.g. 
mislocalization and decreased function). 
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3. INFECTION AND INFLAMMATION IN CF 
 
Although the cystic fibrosis transmembrane ion receptor (CFTR) gene and 
protein have been identified since seventeen years, it remains enigmatic how 
abnormalities in CFTR can cause chronic and persistent pulmonary infection 
and inflammation that lead to bronchiectasis and end-stage lung disease [86]. 
 
3.1 LUNG INFECTION   
 
Healthy airways are sterile below the first bronchial division. Sterility is 
maintained, despite constant challenge from viruses and bacteria in the air that 
we breathe, by an elaborate hierarchy of defenses. Lung defenses are 
understood only in outline. The airway surfaces are covered with a thin film 
(∼30 µm) of airway surface liquid (ASL) consisting of a periciliary sol and a 
mucus gel that are propelled toward the mouth by coordinated ciliary beating. 
Thus, mucociliary clearance, aided by cough, cleans the airways mechanically. 
The ASL is not simply saltwater, but is instead a rich broth of 
proteases/antiproteases, oxidants/antioxidants, antibiotics, and antibodies that 
work together to inactivate or destroy pathogens without undue collateral 
damage to the lungs. These mucosal mechanisms are backstopped by cellular 
immune mechanisms involving dendritic cells, neutrophils, and macrophages 
that are recruited and coordinated by signaling molecules in the ASL.    
Although the complex pulmonary defense system is understood in outline, 
details are lacking because of technical impediments that, together with the lack 
of appropriate animal models, help to explain why we are still struggling to 
understand CF lung disease. The pattern of CF lung disease is unlike that of 
any other lung disease.                            
In patients with cystic fibrosis, progression of lung disease is insidious and 
patients may be relatively asymptomatic before irreversible changes and 
chronic bacterial colonization occur.                
Cough is the predominant symptom in the early stages of cystic fibrosis, 
 occurring in as many as 50% o
many patients do not have pulmonary symptoms. The first detectable evidence 
of lung disease in patients with cystic fibrosis is infection and/or inflammation in 
bronchoalveolar lavage fluid, denoted by elevated counts of interleukin
neutrophils and the presence of microorganisms [88
influenza, Staphylococcus aureus
most prevalent early pathogens, and 
least 1 of these bacteria by 1 year of age 
be transient, and approximately half clear spontaneously 
Chronic colonization with 
function [97, 98], especially if the isolate becomes mucoid 
most patients are initially infected with nonmucoid 
transitions to a mucoid state. Mucoid 
treat and eradicate because it lives in a defensive mode of growth called biofilm 
[102, 103] [fig.13].  
FIGURE 13: The biofilm life cycle
extracellular polymeric substances (
and 4: biofilm architecture develops and matures. 5: single 
 
Biofilms are communities of bacteria, enclosed in a self
attached to a surface 
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 and Pseudomonas aeruginosa
most patients have colonization with at 
[92, 93]. Early infections with 
PAO is associated with a more rapid decline in lung 
[99-
P. aeruginosa
Pseudomonas is much more difficult t
 
 of PAO. 1: individual cells populate the airway 
EPS) are produced and attachment becomes irreversible. 3 
PAO cells are released from the 
biofilm. 
-produced matrix, 
[104]. Bacteria in a biofilm state exhibit increase
; however, 
-8 and 
Haemophilus 
 (PAO) are the 
PAO can 
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101]. Although 
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resistance to antibiotics [105] and host defense factors [106]. Therefore, 
clinically attainable antibiotic concentrations may not adequately clear biofilm 
infections, allowing the bacterial population to recover, persist and spread. 
Microscopic and physiologic evidence supports biofilm formation by P. 
aeruginosa in sputum from patients with cystic fibrosis [107]. Antibiotic-resistant, 
biofilm-forming mucoid P. aeruginosa  are believed to play a dominant role in 
the progression of lung disease in patients with cystic fibrosis [99-101]. 
 
3.2 LUNG INFLAMMATION    
 
The lungs, including mucus glands, are structurally normal at birth [108]. Soon 
after birth excessive endobronchial inflammation in the small airways has been 
demonstrated in both sputum culture positive and sputum culture negative 
patients. Broncho-alveolar lavage (BAL) fluid shows a predominantly neutrophil 
inflammation with elevated interleukin (IL)-8 and neutrophil elastase [109-112]. 
This persistent inflammation is the major cause of progressive lung injury and 
destruction leading to a decrease in lung function. This progressive loss of lung 
function is the main reason for the limited life expectancy of most patients with 
CF.               
Virtually all patients with CF are chronically infected with one ore more bacterial 
species. The inflammatory response to infection appears to be more intense in 
patients with CF compared to non-CF patients. Additionally, it has been shown 
that the number of colony forming units in BAL fluid is directly related to the 
intensity of the inflammatory response with a significant increase in the number 
of inflammatory cells and an increase in IL-8 concentrations [113].     
Acquisition and consequent chronic infection with mucoid strains of P. 
aeruginosa leads to an increase in the endobronchial inflammatory response to 
infection. It has been shown that CF cell lines produce more pro-inflammatory 
cytokines than normal cell lines in response to P. aeruginosa [114]. This 
“overproduction” of pro-inflammatory cytokines can be found in the ELF of CF 
airways [115]. Also significantly lower levels of the anti-inflammatory cytokine 
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IL-10 , which inhibits the production of pro-inflammatory cytokines as IL8 and 
IL6, are found. This imbalance of anti-inflammatory and pro-inflammatory 
cytokines results in an excessive and persistent inflammation in the CF airways. 
As a result lung function deteriorates more rapidly in P. aeruginosa positive 
patients compared with CF patients negative for P. aeruginosa [116, 117].                
For  all these reasons, understanding the pathophysiology of lung inflammation 
and thereby the pathogenesis of lung disease in CF is needed to improve 
current therapies and develop new therapeutic strategies. 
 
3.3 CYTOKINES AND INFLAMMATORY MEDIATORS IN 
CYSTIC FIBROSIS   
 
Airway disease in cystic fibrosis (CF) is characterised by chronic infection and 
an inflammatory response dominated by a neutrophilic infiltrate. There is 
incomplete understanding of the relationship between the abnormal CFTR gene 
product and the development of inflammation and progression of lung disease 
in CF [118]. 
Evidence suggests that airway inflammation in CF is associated with increased 
production of pro-inflammatory cytokines in the lung. Airway epithelial cells, 
macrophages, and neutrophils are all capable of producing cytokines. 
Several studies have found elevated concentrations of proinflammatory 
cytokines such as interleukin-1 (IL-1), IL-6, IL-8, and tumour necrosis factor-
alpha (TNF-α) in the sputum and bronchoalveolar lavage fluid (BALF) of 
patients with CF [118]. Their synthesis is promoted by the transcription factor 
nuclear factor-kB (NF-kB), which plays an important role in intracellular 
signalling for the production of pro-inflammatory cytokines [119]. IL-10, IL-1 
receptor antagonist protein (IRAP), and soluble TNF-α receptor (TNFsR) are 
anti-inflammatory cytokines that are relatively down-regulated in CF airway cells 
[120]. The principle action of IL-10 is to increase the synthesis of I-kB, the 
inhibitor of NF-kB. Downregulation of IL-10 leads to increased proinflammatory 
cytokines due to less inhibition of NF-kB actions [119]. Furthermore we 
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investigated on MCP1 (Monocyte Chemotactic Protein-1, a member of the small 
inducible gene -SIG- family, that plays a role in the recruitment of monocytes to 
sites of injury and infection), RANTES (Regulated on Activation Normal T 
Expressed and Secreted, a protein member of the interleukin-8 superfamily of 
cytokines, that is a selective attractant for memory T lymphocytes and 
monocytes), and G-CSF (Granulocyte Colony-Stimulating Factor, a colony-
stimulating factor that stimulates the production of neutrophils). Table 2 lists the 
actions of both the proinflammatory and anti-inflammatory cytokines. 
 
 
cytokines Action 
IL1 Primes neutrophils 
Increases adhesion of neutrophils to endothelium 
 
IL8 Increases chemotaxis of neutrophils to site of inflammation 
Activates neutrophils 
Increases expression of adhesion molecules 
 
TNFα Increases chemotaxis of neutrophils to site of inflammation 
Increases adhesion of neutrophils to endothelium 
Induces synthesis of chemoattractant neutrophils 
Increases intermediary metabolism 
 
IL6 Mediates acute-phase reaction 
Matures B-lymphocytes 
Activates T-lymphocytes 
 
IL10 Inhibits secretion of TNFa and other cytokines 
Inhibits antigen presentation 
 
IRAP Inhibits IL-1 receptor binding 
Antagonises activities of IL-1 
IL-1, interleukin-1; IL-8, interleukin-8; TNFa, tumour necrosis factoralpha; 
IL-6, interleukin-6; IL-10, interleukin-10; IRAP, interleukin-1 
receptor antagonist protein. 
 
Table 2 – Actions of cytokines. 
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Airway epithelial cells may be involved directly in the excess inflammation by 
several mechanisms. Pro-inflammatory cytokines arise from airway epithelial 
cells, as well as from macrophages and infiltrating neutrophils [Table 3]. 
 
 
 Neutrophils Epithelial cells Macrophages Lymphocytes 
IL-1 β + + +++  
IL-6 + + +++ + 
IL-8 +++ ++ ++ + 
IL-10 
 ++ + ++ 
TNFα ++ + +++ + 
IRAP +  +++  
TNFsR ++ + +  
IL-1β, interleukin-1beta; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, 
interleukin-10; TNFα, tumour necrosis factor-alpha; IRAP, interleukin-1 
receptor antagonist protein; TNFsR, tumour necrosis factor soluble 
receptor  
 
Table 3 – Cellular source of cytokines produced in human airways. 
 
Airway epithelial cells also express large numbers of the important pro-
inflammatory adhesion molecule, ICAM-1. This adhesion molecule is a ligand 
for neutrophils, and adhesion is thought to result in increased IL-8 production, 
leading to persistence of neutrophils in the airway [121]. The fact that epithelial 
cells themselves are involved in cytokine release and are thought to play a 
major role in the local inflammation leads to further speculation that defective 
CFTR function (expressed most importantly in the epithelial cells) may be 
directly related to excessive inflammation. 
 
The cytokines tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), 
interleukin-6 (IL-6) and intercellular adhesion molecule-1 (ICAM-1) have 
important roles in regulating neutrophil migration and the inflammatory response 
[122]: 
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• ICAM-1 
Intercellular Adhesion Molecule-1 (ICAM-1, CD54) is a transmembrane 
glycoprotein molecule of the immunoglobulin superfamily.  The protein is a type 
of intercellular adhesion molecule continuously present in low concentrations in 
the membranes of leukocytes and endothelial cells. Upon cytokine stimulation, 
the concentrations greatly increase. ICAM-1 can be induced by interleukin-1 (IL-
1) and tumor necrosis factor alpha (TNFα) and is expressed by the vascular 
endothelium, macrophages, and lymphocytes.  
In cystic fibrosis, neutrophil migration from the bloodstream into the airway 
occurs through interactions between adhesion molecules on neutrophils and 
ligands on the vascular endothelium. One ligand for the CD11/CD18 leukocyte 
adhesion complex is the intercellular adhesion molecule-l which is expressed by 
endothelial cells [123] as well as by bronchial epithelial cells and alveolar type I 
cell [124-126]. A soluble form of ICAM- 1 (sICAM-1) circulates in the blood and 
is present in the bronchoalveolar lining fluid [127]. sICAM- 1 is often increased 
during inflammation; in particular, its concentration is elevated in tracheal 
aspirates of infants with bronchopulmonary dysplasia [128], as well as in the 
plasma or bronchoalveolar lavage (BAL) fluid of patients with idiopathic 
pulmonary fibrosis, asthma, and sarcoidosis [129-134]. 
 
• IL8 
Interleukin-8 (IL-8) is a protein member of the α-chemokine family. This 
chemokine is one of the major mediators of the inflammatory response and it is 
produced by macrophages and other cell types such as epithelial cells.    
There are more receptors of the surface membrane capable to bind IL-8. The 
most frequently studied types are the G protein coupled serpentine 
receptors CXCR1 and CXCR2. Expression and affinity to IL-8 is different in the 
two receptors (CXCR1 > CXCR2). Toll-like receptors are the receptors of the 
innate immune system. These receptors recognize antigen patterns (like 
lipopolysaccharides -LPS- in gram negative bacteria). Through a chain of 
biochemical reactions IL-8 is secreted and is an important mediator of the 
immune reaction in the innate immune system response.        
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Persistent infection with Pseudomonas aeruginosa increases interleukin-8 
levels and causes dense neutrophil infiltrations in the airways of patients with 
chronic airway diseases, such as cystic fibrosis. Recently, it has been reported 
that nitrite reductase from P. aeruginosa enhances IL-8 gene promoter activity.  
Nitrite reductase enhanced nuclear localization of the NF-kB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) binding complex. Furthermore, 
nitrite reductase induced the degradation of IkBα, the major cytoplasmic 
inhibitor of NF-kB, and the expression of IkBα mRNA. These data support the 
critical role of the activation of NF-kB in nitrite reductase-induced IL- 8 gene 
expression in CF airway epithelium [135,136]. 
 
• IL6 
IL-6 is an interleukin that acts as both a pro-inflammatory and anti-
inflammatory cytokine. It is secreted by T cells and macrophages to stimulate 
immune response to trauma, especially burns or other tissue damage leading to 
inflammation. IL-6's role as an anti-inflammatory cytokine is mediated through 
its inhibitory effects on TNF-alpha and IL-1, and activation of IL-1ra and IL-10. 
In CF patients IL-6 gene is up regulated following infection of CF bronchial 
epithelial cells with P. aeruginosa. It has been demonstrated the ability of 
the P. aeruginosa mitogen, exoenzyme S, to induce proinflammatory and 
immunoregulatory cytokines and chemokines, via NF-kB activation. Exoenzyme 
S strongly induced transcription of proinflammatory cytokines and 
chemokines,such as IL-6 and IL-8, and modest transcription of 
immunoregulatory cytokines. The response occurred early and subsided 
without evolving over time. These data suggest that cells responding 
to exoenzyme S would rapidly express proinflammatory cytokines and 
chemokines that may contribute to pulmonary inflammation in cystic fibrosis 
[137]. 
 
• TNFα 
Tumor necrosis factor-α is a cytokine involved in systemic inflammation and is a 
member of a group of cytokines that stimulate the acute phase reaction.        
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The primary role of TNF-α is in the regulation of immune cells. TNF-α is also 
able to induce apoptotic cell death, to induce inflammation, and to 
inhibit tumorigenesis and viral replication, via NF-kB activation. Dysregulation of 
TNF-α production has been implicated in a variety of human diseases, such as 
cystic fibrosis and cancer [138]. Recombinant TNF is used as 
an immunostimulant.                 
Norman et al. have demonstrated that concentrations of TNF-α are higher in 
plasma from patients with cystic fibrosis than in normal controls and that its 
concentration is increased during episodes of acute respiratory infection. It has 
been found TNF-α in cystic fibrosis sputa, during times of clinical stability, at 
concentrations that have been shown to produce neutrophil migration, 
respiratory burst, and degranulation in vitro [139]. This provides evidence in 
favour of the hypothesis that lung damage, due to chronic infection, is occurring 
during periods of apparent wellbeing. 
 
 3.4 NF-kB IN DEFENSE AND DISEASES 
 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a 
protein complex that controls the transcription of DNA. 
 
 3.4.1 NF-kB: A KEY ROLE IN INFLAMMATION 
 
NF-κB regulates host inflammatory and immune responses and cellular growth 
properties [140] by increasing the expression of specific cellular genes. These 
include genes encoding at least 27 different cytokines and chemokines, 
receptors involved in immune recognition such as members of the MHC, 
proteins involved in antigen presentation, and receptors required for neutrophil 
adhesion and migration [141]. Cytokines that are stimulated by NF-κB, such as 
IL-1β and TNF-α, can also directly activate the NF-κB pathway, thus 
establishing a positive autoregulatory loop that can amplify the inflammatory 
response and increase the duration of chronic inflammation. NF-κB also 
stimulates the expression of enzymes whose products contribute to the 
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pathogenesis of the inflammatory process, including the inducible form of nitric 
oxide synthase (iNOS), which generates nitric oxide (NO), and the inducible 
cyclooxygenase (COX-2), which generates prostanoids [142]. The NF-κB 
pathway is likewise important in the control of the immune response. It 
modulates B-lymphocyte survival, mitogen-dependent cell proliferation, and 
isotype switching, which lead to the differentiation of B lymphocytes into plasma 
cells [143]. In addition, NF-κB regulates IL-2 production, which increases the 
proliferation and differentiation of T lymphocytes [144]. Thus, activation of NF-
κB leads to the induction of multiple genes that regulate the immune and the 
inflammatory response.  
In addition to activating the expression of genes involved in the control of the 
immune and inflammatory response, the NF-κB pathway is also a key mediator 
of genes involved in the control of the cellular proliferation and apoptosis. 
Antiapoptotic genes that are directly activated by NF-κB include the cellular 
inhibitors of apoptosis (c-IAP1, c-IAP2, and IXAP), the TNF receptor–associated 
factors (TRAF1 and TRAF2), the Bcl-2 homologue A1/Bfl-1, and IEX-IL [145]. 
 
3.4.2 NF-kB FUNCTION AND REGULATION  
 
NF-κB is composed of homo- and hetero-dimeric complexes of Rel family 
polypeptides, which are characterized by an N-terminal RHD (Rel homology 
domain), which mediates DNA binding, nuclear localization and subunit 
dimerization [140]. Mammals express five NF-κB proteins, namely RelA (p65), 
RelB, c-Rel, NF-κB1 p50 and NF-κB2 p52 [fig.14A]. NF-κB1 and NF-κB2 are 
synthesized as large precursors of 105 (p105) and 100 kDa (p100) respectively. 
These are partially proteolysed by the proteasome (termed processing), which 
removes their C terminal halves, to produce the active NF-κB1 p50 and NF-κB2 
p52 subunits. RelA and c-Rel both have C-terminal transactivation domains in 
their RHDs and can strongly activate transcription from NF-κB binding sites in 
target genes. RelB also contains a transactivation domain in its RHD and can 
function as an NF-kB activator when complexed with p50 or p52. However, 
RelB/RelA heterodimeric complexes are inhibitory, since they cannot bind DNA 
37 
 
[146]. NF-κB1 p50 and NF-κB2 p52 lack a transactivation domain, and can only 
promote transcription when heterodimerized with a transactivating Rel subunit 
[147]. Homodimers of p50 and p52 function as transcriptional repressors, but 
can stimulate transcription when bound to the IκB-like nuclear protein BCL-3 
[148-150]. 
 
 
 
FIGURE 14 - Schematic representation of members of the Rel/NF-κB (A) and 
IκB (B) families of proteins Rel/NF-κB proteins are characterized by their conserved N-terminal 
RHDs (blue) which mediate DNA binding, nuclear localization and subunit dimerization. 
 IκB proteins each contain ankyrin repeat regions (red), which interact with RHDs of NF-κB 
subunits to prevent nuclear translocation. The numbers of amino acids in each protein are 
shown on the right. In (A) arrowheads point to the C-terminal residues of p50 and p52, which 
are produced by proteolytic processing of the C-terminal halves p105 and p100 respectively 
(grey shading). In (B) the positions of the IKK phosphorylation sites, which regulate the 
inducible proteolysis of IκB proteins, are shown. LZ, leucine zipper; TD, transactivation domain. 
 
In unstimulated cells, NF-κB dimers are inactive, since they are sequestered in 
the cytoplasm by interaction with inhibitory proteins termed IκBs (inhibitors of 
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NF-κB) [140]. In response to stimulation with agonists, IκBs are proteolytically 
degraded by the proteasome, releasing associated NF-κB dimers to translocate 
into the nucleus and modulate gene expression [fig.15]. The transcriptional 
activity of certain NF-κB dimers is additionally regulated by phosphorylation, 
providing an extra level of control of NF-κB activation [151]. 
 
 
 
 
FIGURE 15 -  Model of the generic NF-κB activation pathway 
Various stimuli induce the phosphorylation (-℗) and subsequent polyubiquitination (-Ub) of 
IκBs, which are then targeted for degradation by the 26S proteasome. Associated NF-κB dimers 
are thereby released to translocate into the nucleus, where they bind to the promoter regions 
of NF-κB-responsive genes to modulate their expression. The transactivating capacity of 
nuclear NF-κB dimers can also be regulated by phosphorylation. 
 
IκBs comprise a family of structurally related proteins, each of which contain 
multiple ankyrin repeats that interact with the nuclear localizing signals of RHDs 
to prevent nuclear translocation of Rel subunits [fig.14B]. This family includes 
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IκBα, IκBβ and IκBε, which are composed of a central ankyrin repeat region and 
an N-terminal regulatory domain, which controls their inducible degradation. 
The precursor NF-κB proteins, NF-κB1 p105 and NF-κB2 p100, also function as 
IκBs as a result of ankyrin repeat regions in their C-terminal halves. Alternate 
promoter usage of the NF-κB1 gene can generate an mRNA encoding only the 
C-terminal IκB-like portion of p105, termed IκBγ, but this has so far only been 
reported in murine cells [152, 153]. 
 
3.4.3 INHIBITION OF NF-kB: A STRATEGY IN ANTI-
INFLAMMATORY THERAPIES 
 
The induction of proinflammatory genes usually results from the increased 
activity of a subset of transcription factors that have thus become attractive 
targets in the development of novel anti-inflammatory drugs. Among the 
inducible transcription factors that control inflammatory gene expression, 
nuclear factor NF-kB plays a central and evolutionarily conserved role in 
coordinating the expression of various soluble proinflammatory mediators (as 
cytokines and chemokines) and leukocyte adhesion molecules [140]. 
A wide range of genes involved in inflammation contain functional kB-sites 
within their promoters and are induced by NF-kB [154]: thus, NF-kB could be 
proposed as one target to down-modulate the immune processes involved in 
different pulmonary diseases, including CF [155], by using of drugs, synthetic 
molecules, natural products and normal or recombinant proteins that could act 
at several steps to interfere with NF-kB activation [fig.16]. 
Various classes of NF-kB inhibitors are discussed below:  
 
• NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) 
 
Acetylsalicylic acid (ASA) and sodium salycilate function as an anti-
inflammatory agents by inhibiting cyclooxygenase (COX), an enzyme activity 
essential to the production of prostaglandins (PGs) [156]. More recent studies 
demonstrate that the mechanism of inhibition by both ASA and sodium 
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salycilate occurs by means of binding and blocking the ATP binding site of IKKβ 
[157]. Intriguingly, expression of the COX-2 encoding gene, believed to be 
responsible for the massive production of PGs at inflammatory sites, is 
transcriptionally regulated by NF-kB [158, 159]. The ability of ASA and sodium 
salicylate to inhibit NF-kB activity and kB-dependent gene expression has been 
tested experimentally in a wide range of cell types and conditions. For example, 
pretreatment of primary synovial fibroblasts or lung epithelial cells with ASA 
blocks IL-1β and TNF-α – induced NF-kB activation so that the subsequent 
expression of IL-6 and IL-8 is inhibited [160, 161]. 
Furthermore Ibuprofen inhibits NF-kB activation in T cells [162] as well as COX-
2 expression and PGE2 production in murine macrophages. Among the other 
NSAIDs that have been investigated, acetaminophen inhibits the binding of NF-
kB to DNA in LPS- and interferon-γ – treated macrophages and thus precludes 
expression of inducible nitric oxide synthase [163]. Moreover, sulindac, an 
NSAID that is both structurally and pharmacologically related to indomethacin, 
decreases IKKβ kinase activity and consequently inhibits NF-kB activation 
[164]. Lastly, tepoxalin, which inhibits both COX and 5-lipoxygenase, blocks NF-
kB activation in Jurkat T-cells and HeLa cells.  
Thus, the findings that salicylates and glucocorticoids can inhibit NF-kB activity 
are among a growing body of data indicating that drugs specifically designed to 
target NF-kB activation might be clinically useful for the treatment of diseases 
that involve inflammation, as cystic fibrosis [165-169]. 
  
• GLUCOCORTICOIDS 
 
Glucocorticoids (GCs) and other corticosteroids are the most widely used anti-
inflammatory, immunosuppressive drugs. GCs function to downregulate the 
expression of genes involved in inflammation [170]. Previous studies 
demonstrated that GCs increase the expression of an IkB molecule, named 
IkBα, so that NF-kB is retained in the cytoplasm and thus rendered inactive 
[165, 167].  
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The notion that NF-kB inhibition underlies the anti-inflammatory capacity of GCs 
is also supported by animal studies. In a mouse model of acute inflammation 
(carrageenin - induced air pouch inflammation), treatment with the synthetic 
steroid dexamethasone reduces the number of cells that stain positively for 
activated NF-kB [171]. In rats, dexamethasone not only inhibits TNF-α 
production and hepatic NF-kB activation associated with peritoneal sepsis [172], 
but also inhibits LPS-induced activation of NF-kB, restores myocardial 
contractility, and increases myocardial IkBα protein levels [173]. Finally, a 
recent study of normal human subjects demonstrates that intravenous injection 
of hydrocortisone increases IkBα levels and reduces the translocation of NF-kB 
into the nuclei of peripheral mononuclear cells [174], which supports the 
experimental model originally proposed for the molecular action of GCs [165, 
167]. 
 
• ANTIOXIDANTS 
 
The generation of reactive oxygen species (ROS) by phagocytic leukocytes 
(neutrophils, monocytes, macrophages, and eosinophils) is one of the most 
important hallmarks of the inflammatory process. By oxidizing essential cellular 
components of invading pathogens, reactive radicals and oxidants also 
represent the first line of defense against microorganisms [175]. In addition to 
promoting general cytotoxicity, ROS may also act to upregulate proinflammatory 
gene expression by activating NF-kB, a process that is itself sensitive to the 
cellular redox state [176]. 
Diverse agents that cause oxidative stress can activate NF-kB [177], and 
numerous stimuli that activate NF-kB, including cytokines, phorbol esters, LPS, 
and CD3 engagement, increase the levels of intracellular ROS [178]. This 
generation of ROS, however, is cell- and stimulus-specific. Thus, whereas 
stimulation with the proinflammatory cytokines IL-1 and TNF-α leads to 
substantial intracellular ROS in lymphoid and monocytic cell lines, no such 
increases have been observed in epithelial cell lines derived from ovaries, 
colon, breast, or cervix [178]. 
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• ANTISENSE OLIGODEOXYNUCLEOTIDES  
 
Antisense oligodeoxynucleotides constitute a potentially important family of 
therapeutic compounds for the treatment of a range of diseases [179]. The use 
of antisense technology to inhibit expression of NF-kB proteins has been 
evaluated both in vitro and in vivo in a variety of experimental systems. 
Antisense targeting of the NF-kB p50 subunit can reduce IgM and IgG synthesis 
in B cells [180], and can significantly reduce maturation and proliferation of 
CD25/IL-2R T-cells [181]. Antisense strategies to reduce expression of the p65 
subunit greatly inhibits the expression of cell adhesion molecules in endothelial 
and smooth muscle cells in vitro [182]. In vivo, antisense inhibition of p65 blocks 
tumor growth in nude mice, prolongs allo- and xenograft survival [183, 184], and 
alleviates septic shock in LPS-treated animals [185, 186]. Clearly, the 
therapeutic potential of antisense molecules directed against NF-kB and the 
components required for its expression and activation warrants further 
investigation. 
 
• PROTEASOME INHIBITORS 
 
Signal-induced phosphorylation and ubiquitination of IκB and its degradation by 
the 26S proteasome precede NF-κB nuclear translocation. Inhibitors of 
proteasome function reduce the degradation of IκB to prevent activation of the 
NF-κB pathway. A variety of peptide aldehydes, including MG101, MG132, and 
MG115, make up one class of agents that inhibit the protease activity of the 
proteasome [187, 188].  
Proteasome inhibitors of another class, including lactacystin, block protein 
degradation activity by acylating a threonine residue in one of the key 
proteasome subunits. Finally, a group of boronic acid peptides, including PS-
341, are extremely potent inhibitors of proteasome function [189, 190]. 
Recently, PS-341 has shown promise as an adjunct to cancer chemotherapy by 
inhibiting activation of the NF-κB pathway. It is also possible that inhibitors of 
the ubiquitin ligase that mediates IκB ubiquitination may be a useful target in 
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preventing proteasome degradation of IκB. Thus, a variety of potential inhibitors 
of proteasome function may have a role interrupting the NF-κB pathway. 
 
 
FIGURE 16 - Inhibition of the NF-κB pathway. A schematic illustrating the steps 
involved in the activation of the NF-κB pathway. Numerous drugs, natural 
products, and normal or recombinant proteins can act at several of 
these steps to interfere with NF-κB activation. 
 
In our lab, we focused our attention on two different strategies with the aim of 
down-regulate the pro-inflammatory gene expression: 
• transcription factor decoy (TFD) 
• natural products as source of new anti-inflammatory componuds 
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3.5 OLIGODEOXINUCLEOTIDES AS THERAPEUTIC DECOYS 
 
Synthetic oligonucleotides have recently been the object of many investigations, 
aimed to develop sequence-selective molecules able to modulate, either 
positively or negatively, transcription of eukaryotic genes. Alteration of 
transcription could be obtained by using synthetic oligonucleotides mimicking 
target sites of transcription factors (the transcription factor decoy -TFD- 
approach). This could lead to either inhibition or activation of gene expression, 
depending on the biological functions of the target transcription factors. 
Because transcription factors can recognize their relatively short binding 
sequences even in the absence of surrounding genomic DNA, short double-
stranded oligodeoxynucleotides (ODNs) bearing the consensus binding 
sequence of a specific transcription factor have been explored as tools for 
manipulating gene expression in living cells [fig.17].  
 
 
 
FIGURE 17 - Under a stimulus, there is a receptor mediated activation of the IKK complex, that 
induces a phosphorylation of  IkBα (1), that leaves NF-kB and allow it to enter the nucleus(2) 
and binding specific sequences (3), starting the transcription of specific genes and mRNA (4-5). 
If specific sequences, complementary to the consensus region on gene target promoter to which 
the transcription factors bind, are injected into the cells, there is a block in the specific gene 
transcription. 
 
These synthetic decoys "compete" for binding of the transcription factor with 
consensus sequences in target genes. If delivered into the cell in sufficient 
concentrations these "decoys" thus have the potential to attenuate the binding 
of the transcription factor to promoter regions of target genes and thus 
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attenuate the function of the transcription factor to regulate the expression of its 
target gene(s). Transfected at high concentrations these decoys have been 
reported in the literature to completely block transcription factor function. Clearly 
they represent powerful research tools for studying gene regulation both in vitro 
and also more recently in vivo [191, 192]. 
Yoshimura et al. reported the successful in vivo transfer of NF-kB decoy ODN to 
reduce neointimal thickening in rat carotid artery model, providing a new 
therapeutic strategy for restenosis after angioplasty. Since a rapid and transient 
activation of NF-kB after balloon injury plays a crucial role in the formation of 
neointima, they demonstrated that inhibition of transient NF-kB activation should 
be a new therapeutic tool. To block NF-kB activation, they utilized a ‘decoy’ cis 
element, since decoy ODN can bind NF-kB and thereby block its activation. 
Using this technology, they already reported the successful inhibition of NF-kB 
activation in a rat myocardial infarction model [193]. Therefore, they examined 
the inhibition of NF-kB activation after balloon injury by in vivo transfection of 
NFkB decoy ODN into balloon-injured blood vessels. As expected, it was 
observed that activation of NF-kB in the injured vessels was successfully 
inhibited by NF-kB, but not scrambled, decoy ODN in vivo. These studies reveal 
the importance of NFkB activation in neointimal formation after vascular injury, 
since transfection of NFkB decoy ODN inhibited neointimal formation 
accompanied by a decrease in NFkB activity. 
Furthermore, Penolazzi et al. reported the in vivo effects of a decoy 
oligonucleotide targeting the nuclear factor κB (NF-κB) on osteoclasts during 
forced orthodontic tooth movement in rats [194]. Wistar rats were subjected to 
orthodontic forces, in the absence or presence of treatment with a decoy 
molecule mimicking a nonsymmetric NF-κB binding site (5'-CGC TGG GGA 
CTT TCC ACG G-3'). TUNEL staining of fragmented DNA revealed that 
treatment with NF-κB decoy but not with scramble double-stranded 
oligodeoxynucleotides (ODN) induced a high level of osteoclast apoptosis in 
vivo. Immunohystochemical analysis for death receptor Fas revealed strong 
positivity only in samples treated with NF-κB decoys, demonstrating that 
osteoclasts are sensitive to death induction via Fas signaling. Induction of 
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apoptosis in osteoclasts could be a strategy for treatment of excessive 
osteoclast activity in pathologic conditions such as osteoporosis, peri-articular 
osteolysis, inflammatory arthritis, Paget's syndrome and tumour-associated 
osteolytic metastases. 
Moreover, the lung Infection with P. aeruginosa is known to induce expression 
of genes of the innate immunity by activating different TFs, such as NF-kB, AP-
1, Elk-1, and NF–IL-6 [195-197]. Since NF-kB plays a well known pivotal role in 
inflammatory processes, we choose it as the first molecular target for the TF 
decoy approach.  
 
3.6 NATURAL PRODUCTS 
 
Classic therapies based on corticosteroids [170] and ibuprofen [162], as well as 
chemiotherapy, have been employed in CF patients, but they have 
demonstrated limited efficacy or occurrence of undesired effects, suggesting the 
importance of investigations aimed at identifying alternative therapeutic targets 
and novel anti-inflammatory molecules [198, 199, 200-203]. 
In this respect, we are studying natural products as sources for the discovery of 
new drugs on the basis of their widespread application in ethnic and traditional 
medicine to cure several human diseases, such as muscular and neuronal 
diseases, mycosis, heart and respiratory diseases, atherosclerosis [204-206]. 
As an activator of many pro-inflammatory cytokines and inflammatory 
processes the modulation of the NF-kB transduction pathway is a principal 
target to alleviate the symptoms of such diseases as arthritis, inflammatory 
bowel disease and asthma. Natural products and some extracts are reviewed 
and assessed for their activity and potency as NF-kB inhibitors. A large number 
of compounds are currently known as NF-kB modulators and include the 
isoprenoids, most notably kaurene diterpenoids and members of the 
sesquiterpene lactones class, several phenolics including curcumin and 
flavonoids such as silybin. Additional data on cellular toxicity are also 
highlighted as an exclusion principle for pursuing such compounds in clinical 
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development. In addition, where enough data exists some conclusions on 
structure-activity relationship are provided. 
The treatment of inflammatory conditions with plants is widely reported [207-
209]. Natural products are already providing lead compounds in the search for 
inhibitory small molecules but only a few are beginning to be commercially 
used. One example is a veterinary product under development for the treatment 
of canine osteoarthritis (Phytopharm 2001a) and inflammatory bowel disease 
(Phytopharm 2001b). 
There are a multitude of approaches for identifying new pharmaceuticals. In the 
field of natural product biology, ethnopharmacological as well as bioprospecting 
approaches have received renewed attention in recent years. The concept of 
ethnopharmacology specifically aims to develop plant-based drugs for more 
widespread local use either as pure compounds or plant extracts (phytotherapy) 
[210]. Concurrent with this analysis is the requirement for the documented use 
of useful plants by indigenous peoples (ethnobotany). 
Thus, screening libraries of plant extracts for their anti-inflammatory activity, in 
suitable respiratory epithelial cells in vitro and pre-clinical animal models in vivo, 
could select candidate molecules of potential therapeutic effect. These anti-
inflammatory molecules for respiratory diseases could be administered both 
systemically (e.g. orally) or locally (e.g. by aerosol). 
In our lab, we investigated the anti-inflammatory effect of a series of medicinal 
plant extracts, including Bergamot from Lebanon, Emblica officinalis and Saraca 
asoka from Bangladesh 
 
3.6.1 BERGAMOT 
 
Bergamot is a small and roughly pear-shaped citrus fruit, [fig.18] growing on 
small trees known as bergamots (Citrus bergamia Risso, Rutaceae).  
Bergamot plants, despite their uncertain species definition and 
phytogeographical origin, are mainly cultivated in Ionian coastal regions of 
southern Italy, Argentina, and Brazil for their fruits. Bergamot fruits are 
traditionally employed as raw material in cosmetics and cosmeceutics because 
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of their essential oil flavor and in dietary and herbal products as crude drugs 
because of the eupeptic properties and therapeutic activities against digestive 
disorders [211]. 
 
 
FIGURE 18 – Citrus Bergamia. 
 
In the past, Bergamot essential oil has been used in the folk medicine as 
antiseptic, to facilitate wound healing and as antihelminthic. Actually, likewise 
other essential oils, Bergamot essential oil is widely used in aromatherapy, a 
complementary medicine highly diffused in the industrialized countries to 
improve mood and mild symptoms of stress-induced disorders such as 
anxiety [212], depression [213], behavioural disturbances in dementia [214] and 
chronic pain [215, 216]. Individual components of essential oils reach the blood, 
cross the blood-brain barrier and enter the central nervous system (CNS) 
following inhalation, dermal application [217], intraperitoneal (i.p.) or 
subcutaneous (s.c.) injection and oral administration [218]. Physiological and 
pharmacological studies, combined with phytochemical analyses, indicate that a 
variety of essential oils exert specific effects on the CNS [219]. 
Recently, Hiroyasu Inoue et al. have released a study confirming the 
inflammation reducing power of many aromatherapy essential oils. The oils 
shown to reduce inflammation through suppression of the COX-2 pro-
49 
 
inflammatory enzyme included herbs, like thyme, clove and fennel; rose; 
eucalyptus; and even the citrus bergamot. They suppress the inflammation 
COX-2 mediated in a manner similar to resveratrol, the chemical linked with the 
health benefits of red wine. The oils considered to have the strongest anti-
inflammation activity used in aromatherapy were not even examined, which can 
mean that there are naturally a great many compounds found in essential oils 
that have an anti-inflammatory effect [220]. 
 
3.6.2 EMBLICA OFFICINALIS 
 
Emblica officinalis is commonly known as Amla or the Indian gooseberry 
[fig.19], which is a member of a small genus Emblica (Family Euphorbiaceae) 
and is extensively found all over India, as well as Sri Lanka, Malaysia, China, 
Pakistan and Bangladesh.  
 
 
 
 
FIGURE 19 – Emblica Officinalis. 
 
The tree is small to medium sized, reaching 8 to 18 m in height, with a crooked 
trunk and spreading branches. The branchlets are glabrous or finely pubescent, 
10–20 cm long, usually deciduous; the leaves simple, subsessile and closely 
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set along branchlets, light green, resembling pinnate leaves. The flowers are 
greenish-yellow. The fruit is nearly spherical, light greenish yellow, quite smooth 
and hard on appearance, with 6 vertical stripes or furrows. 
The fruits of Emblica officinalis  have been reported to contain constituents with 
variable biological activity: they have been used for thousands of years in the 
traditional Indian medicine for the treatment of several diseases. For many 
years the therapeutic potential of the fruits was attributed to their high content of 
ascorbic acid: about 1 g of vitamin C per 100 ml of fresh juice. 
In 1996 professor Shibhnath Ghosal of Banaras Hindu University discovered 
that Emblica fruits do not contain ascorbic acid neither in free nor in conjugated 
form, but it contains two new hydrolysable tannins with low molecular weight 
(B1000), called emblicanin A (2,3-di-o-galloyl-4,6-(S)-hexahydroxydiphenoyl-2-
keto-glucono-d-lactone) and emblicanin B (2,3,4,6-bis-(S)-
hexahydroxydiphenoyl-2-keto-glucono-d-lactone) and other tannins like 
punigluconino (2,3-di-O-galloyl-4,6-(S)-hexahydroxydiphenoylgluconicacid) and 
pedunclagin (2,3,4,6-bis-(S)-hexahydroxydiphenoyl-D-glucose) already isolated 
in other species, Punica granatum in particular. These two new tannins have a 
very strong antioxidant action. The two emblicanins A and B have been found to 
preserve erythrocytes against oxidative stress induced by asbestos, generator 
of superoxide radical. Emblicanin A oxidates when put in contact with asbestos 
becoming emblicanin B and together they have a stronger protective action to 
erythrocytes than vitamin C. Moreover they improve the efficacy of vitamin C in 
reducing dihydroascorbic acid to ascorbic acid. 
The same recycling process has been observed in the rutin-vitamin C 
combination. Fruit extract has been shown to have an antimutagenic activity in 
Ames test. Recently fruits have been tested for their antiviral activity, particularly 
for inhibiting reverse transcriptase in the replication of retroviruses like HIV-1. 
Some active ingredients inhibit the replication of the virus through a non 
competitive action with respect to the dTTP but competitive action with respect 
to the template primer. 
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Other studies have shown that the fruit enhances the immunodefence and has 
a hypolipidemic effect. Emblica fruit is also effective in acute pancreatitis 
therapy and like hepatoprotective [221-229]. 
Recent studies by Sachdanandam et al. illustrated the beneficial outcome of the 
Siddha drug Kalpaamruthaa (KA) in reducing the pathological lesions caused by 
the proinflammatory cytokines in adjuvant induced arthritis (AIA) in rats. KA, 
consisting of Semecarpus anacardium nut milk extract (SA), dried powder 
of Emblica officinalis fruit and honey, significantly regulated the inflammation in 
arthritic joints by reducing extracellular matrix degradation and cartilage and 
bone destruction via down regulating the levels of TNF-a and IL-1β, as well the 
levels of acute phase proteins with appreciable increase in the levels of 
immunoglobulins in arthritic rats [230]. 
 
3.6.3 SARACA ASOKA 
 
The Ashoka tree (Jonesia Ashok or Sarac Indica) is a plant belonging to 
the Caesalpiniaceae subfamily of the legume family [fig.20]. It is an important 
tree in the cultural traditions of the Indian Subcontinent and adjacent areas. 
 
 
FIGURE 20 – Saraca asoka plant and fruits. 
As a wild tree, the asoka is a vulnerable species. It is becoming rarer in its 
natural habitat, but isolated wild asoka trees are still to be found in the foothills 
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of central and eastern Himalayas, in scattered locations of the northern plains of 
India as well as on the west coast of the Subcontinent near Mumbai. 
The asoka tree is considered sacred throughout the Indian subcontinent, 
especially in India and Sri Lanka. This tree has many folklorical, religious and 
literary associations in the region. Highly valued as well for its handsome 
appearance and the color and abundance of its flowers, the asoka tree is often 
found in royal palace compounds and gardens as well as close to temples 
throughout India. The asoka tree has a symbolic importance 
in Buddhism. Queen Māyā of Sakya is said to have given birth to 
the Buddha under an asoka tree in a garden in Lumbini.  
The earliest chronicled mention is in the Ayurvedic treatise, the Charka Samhita 
(100 A.D.), in which Asoka is recommended in formulations for the 
management pain with relation to uterus (gynecological) as anodynes. The 
Bhavprakasha Nighantu, commonly known as the Indian Materia Medica (1500 
A.D.), cites the plant as a uterine tonic: actually Saraca asoka is very famous for 
its use in treating gynecological disorders, it is known as an astringent to treat 
excessive uterine bleeding from various causes (including hormone disorders 
and fibroids), but also for regulating the menstrual cycle and, in various complex 
formulas, as a tonic for women. The bark, rich in tannins and cyanidins (red 
colored compounds), is the primary medicinal part [231-233]. 
Chloroform, methanol, aqueous and ethanolic extracts of the stem bark of 
Saraca indica were investigated for their antibacterial and antifungal activity 
against standard strains of Staphylococcus aureus, Escherichia coli, 
Pseudomonas aeruginosa, Bacillus cereus, Klebsiella pneumoniae, Proteus 
mirabilis, Salmonella typhimurium and Streptococcus pneumoniae and the 
fungi: Candida albicans and Cryptococcus albidus. Methanolic and aqueous 
extract exhibited antimicrobial activity with MIC ranging from 0.5-2% and 1-3% 
respectively. Methanolic extract exhibited the strongest activity against both 
bacteria and fungi [234]. 
 
Different forms of uses of Asoka herb are described: 
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• Asoka fresh or dried bark: it is bitter, astringent and sweet in taste. It has 
stimulating effect on endometrial and the ovarian tissue. It is useful in 
internal bleeding, hemorrhoids, ulcers, uterine affections, menorrhagia 
especially due to uterine fibroids, meno-metrorrhagia, leucorrhoea and 
pimples. 
• Asoka fresh flower: it is an excellent uterine tonic and is used in cervical 
adenitis, biliousness, syphilis, hyperdipsia, burning sensation, 
hemorrhagic dysentery, piles, scabies in children and inflammation. 
• Asoka dried flowers: they are used in diabetes. 
• Asoka seeds: they are used in treating bone fractures, strangury and 
vesicle calculi. 
 
We suggest that  Saraca asoka, with its lengthy history of human use in 
traditional medicine, deserves consideration as a candidate drug for 
suppressing IL-8-dependent lung inflammation in CF. 
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AIM OF THESIS 
 
Cystic fibrosis is an autosomal recessive genetic disorder common in 
Caucasian population caused by mutations in the CFTR gene and 
characterized by extensive lung inflammation. One of the hallmarks in CF is a 
chronic infection sustained by strikingly few pathogens including 
Staphylococcus aureus and Haemophilus influenzae, whereas in the course of 
their lifetime CF patients become progressively colonized by Pseudomonas 
aeruginosa. Elevated concentrations of pro-inflammatory cytokines and 
chemokines have been found in the bronchoalveolar fluid of patients with CF 
[118, 119]. Consistent with these findings, experimental models support the 
concept that interaction of P.aeruginosa with CF respiratory epithelial cells 
promotes PMN recruitment, mainly by releasing the chemokine interleukin 8 (IL-
8) [116, 117]. Within the lumen of CF airways, nucleic acids derived from PMNs 
further reduce mucociliary clearance, and proteases released from PMNs 
mediate epithelium injury, progressive bronchial wall damage, bronchiectasis, 
and peribronchiolar fibrosis. Therefore, the exaggerated, PMN-dominated 
inflammatory process is thought to critically contribute to the gradual decline in 
CF lung function [113, 114].             
Novel pharmacological correctors and potentiators of mutated CFTR protein 
leave many unanswered questions concerning their application in CF, including 
the degree of correction of the defect that can be obtained, the safety in long 
term administration and the efficacy in reverting the extensive lung inflammatory 
pathology [86]. Although anti-bacterial therapy has been shown to be more 
promising since early eradication therapy has been established in some 
centers, it remains questionable whether all patients will profit from this strategy 
[30-33]. In addition, besides the fact that anti-inflammatory molecules have 
demonstrated potential benefits in CF patients, enthusiasm has been tempered 
either by the limited efficacy or the occurrence of undesired effects.       
Therefore considering that at present no fully satisfactory anti-inflammatory 
treatment is available for clinical use in CF patients, investigation on novel anti-
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inflammatory molecules for the treatment of lung inflammation is considered a 
major priority in the CF community (www.cff.org).                  
With respect to pro-inflammatory mechanisms, P. aeruginosa is known to 
stimulate surface respiratory epithelial cells to express and release IL-8 through 
activation of the transcription factor NF-kB [114, 115]. Besides IL-8, a large 
number of other genes contain kB sites in their 5’-upstream untranslated 
regions, including genes encoding cytokines, chemokines, and adhesion 
molecules that orchestrate PMN transbronchial migration, such as TNF-α, IL-1, 
GRO-γ, and intercellular adhesion molecule (ICAM)-1, together with different 
other genes regulating innate immunity. Thus, NF-kB has been proposed as 
one target to down-modulate the immune processes involved in different 
pulmonary diseases, including CF.         
The transcription factor (TF) decoy approach has been proposed to modulate 
gene expression in vitro. This approach is based on the intracellular delivery of 
double-stranded oligodeoxynucleotides causing inhibition of the binding of TF 
related proteins to the different consensus sequences in the promoter of 
specific genes. Several decoy oligodeoxynucleotides have been studied to 
pursue the modulation of expression of genes relevant to human diseases. Due 
to its central role in immune response and cell cycle regulation, TF decoy 
oligodeoxynucleotides targeted to NF-kB have been studied in other and our 
laboratories [118-121].               
To date, the inhibition of IL-8 expression by NF-kB decoy molecules has been 
limited both conceptually, by the potential lack of specificity related to the wide 
role of NF-kB in regulating expression of several genes, and practically, by the 
limited efficiency obtained in the preliminary experiments [235-237]. Thus, we 
addressed the issues of efficiency and specificity by testing the effect of novel 
NF-kB decoy sequences on the expression of different genes induced by P. 
aeruginosa in human bronchial epithelial cells carrying either the wild type or 
the mutant CFTR gene.             
An other approach has been studied in our lab to modulate the pro-
inflammatory gene expression in vitro. This second approach is based on 
extracts from plants used in ethnic medicine that are of great interest, as many 
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of them are known to retain anti inflammatory properties. This was reviewed by 
Darshan and Doreswamy [238], who reported about the anti inflammatory 
activity of drugs derived from 38 medicinal plants. In this review a clear role of 
botanical plants (including polysaccharides, terpenes, curcuminoids and 
alkaloids) was reported as alleviating inflammatory diseases, such as arthritis, 
rheumatism, acne skin allergy and ulcers. The most potent in curing 
inflammatory diseases were found to be plants containing polysaccharides 
[238]. In the present study, we analyzed the effects of Bergamot, Emblica 
officinalis and Saraca asoka extracts on the production of cytokines and 
chemokines in cystic fibrosis IB3-1 cells [239-241] induced to hyper secretion of 
inflammatory cytokines and chemokines by TNF-α [242-244].                     
In our studies we investigated the ability of the plant extracts and their main 
constituent drugs derived, to interfere with specific bindings between target 
DNA sequences and Rel/NF-kB proteins by EMSA assays (Electrophoretic 
Mobility Shift Assay). To use this compound for in vitro experiments, anti-
proliferative assays have been made in cystic fibrosis IB3-1 cells model.      
After determining the IC50 values (concentrations of extracts leading to 50% 
inhibition of IB3-1 cell growth), we analyzed the inhibitory effect of these 
compounds on gene expression of interleukin 8 (IL8) that is directly involved in 
the inflammation pathway via NF-kB activation. In particular, IB3-1 cells have 
been treated with different concentration of Bergamot,  Emblica officinalis, 
Saraca asoka plant extracts and with increasing concentration of their main 
identified constituents bergamottin, bergapten, citropten, pyrogallol, 5-OH-
isoquinoline, digitoxin; the isolated RNA has been retro-transcribed (Retro-
Transcription PCR) and amplified for the gene of interest IL-8 and the 
housekeeping GAPDH (glyceraldehyde-3-phosphate dehydrogenase).        
The plant extracts resulted more interesting have been used on IB3-1 cells 
induced with TNF-α (Tumor Necrosis Factor-α) to evaluate the inhibitory activity 
in this inflamed cellular model, since previous studies demonstrated that TNF-α 
cytokine, present in high concentration in CF patients, induces inflammatory 
mediators expression. Finally, Bio-Plex technology has been used to analyze 
the potential inhibitory effect of plant extracts on the expression of cytokines in 
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IB3-1 cells induced by TNF-α. The Bio-Plex suspension array system helps to 
reveal a more complete view of the effects of candidate drugs on the biology of 
cells.  
 
58 
 
MATERIALS AND METHODS 
 
1. CELL CULTURES 
 
IB3-1 cells (LGC Promochem), derived from a CF patient with a 
DF508/W1282X mutant genotype, were immortalized with adenovirus 12-SV40 
[fig.21]. The cells were grown in LHC-8 basal medium (Biofluids), supplemented 
with 5% FBS in the absence of gentamycinin in a humidified atmosphere of 5% 
CO2 in air and 37°C [239]. Treatment with TNF- α (80 ng/ml) was performed on 
70% confluent cells for 24 hours to induce the inflammation on IB3-1 cells. 
 
FIGURE 21 – IB3-1 cells 
 
2. CELL INFECTION WITH PSEUDOMONAS AERUGINOSA 
 
PAO1, a well-characterized, nonmucoid motile laboratory strain of P. 
aeruginosa, kindly donated by Alice Prince (Columbia University, New York, 
New York), was grown in trypticase soy broth (TSB) or agar (TSA) (Difco, 
Detroit, MI) [239]. Bacteria colonies from overnight cultures on TSA plates were 
grown with shaking in 20 ml TSB broth at 37°C until  an optical density (at 660 
nm) corresponding to 1 x 109 colony-forming units (CFU)/ml was reached, as 
determined by dilution plating. Bacteria were washed twice in PBS and finally 
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diluted in each specific serum-free culture medium before infection. All cell lines 
were infected with ranging doses of PAO1 at 37°C fo r 4 hours. 
 
3. DECOY OLIGODEOXYNUCLEOTIDES 
 
Decoy oligodeoxynucleotides (ODNs) mimicking the NF-kB consensus 
sequences identified in the HIV-1 long terminal repeat (LTR) of the promoter 
region of HIV-1 gene (sense: 5’-CGC TGG GGA CTT TCC ACG G-3’) were 
used. A ‘‘scrambled’’ ODN sequence (sense: 5’-CAC AAA GTG TAA CAG TCT-
3’) was used in each experiment. Synthesis and high-performance liquid 
chromatography–grade purification was obtained from Sigma. Sense and anti-
sense freeze-dried ODNs were resuspended in DNAse-free sterile water at the 
stock concentration 5 mg/ml. Annealing to obtain double-stranded ODNs was 
performed by mixing equimolar concentrations of both forward and reverse 
strands (1 mg/ml in 150 mM NaCl, final concentration), incubating the solution 
at 100°C for 5 minutes, then leaving it overnight a t room temperature. 
 
4. TRANSFECTION OF CELLS WITH DECOY ODNS 
 
IB3-1 cells have been transfected with ODNs by mixing the double-stranded 
ODNs with the cationic liposome Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA). Lipofectamine 2000 (4ml) was diluted in 1ml LHC-8 serum-free cell culture 
medium (Biofluids), according to the manufacturer’s instructions. Double-
stranded decoy or scrambled ODNs (2 mg) were added and incubated for 10 
minutes. Liposome:DNA complexes in LHC-8 serum-free medium were added 
to IB3-1cells and incubated at 37°C and 5% CO 2 for 6 hours. The cells were 
washed twice with culture serum-free medium and left at 37°C and 5% CO 2 for 
a further 18 hours before infection with P. aeruginosa. 
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5. PLANT EXTRACTS AND CHEMICAL   
 
Bergamot oil was extracted by cold pressing of peels, and it is made up of 93-
96% volatile compounds high quantities of oxygenated compounds.      
The dried fruits of Emblica officinalis were extracted with absolute ethanol and 
the yield was 9.33%.             
The stem barks of Saraca asoka were also extracted with absolute ethanol and 
the obtained yields were 14.16%.        
Bergamottin, bergapten and citropten were purchased from Extrasynthese 
(Lyon, France) and resuspended in ethanol and 3% dimethil-sulfoxide (DMSO). 
Pyrogallol, 5-OH-hydroquinoline, Digoxin were furnished from Sigma-Aldrich 
(Milwaukee, WI, USA) and resuspended in water (pyrogallol) or methanol (5-
OH-hydroquinoline and digoxin). All the resuspended compounds were 
conserved at -20°C protected from light. 
 
6. ASSAYS OF IN VITRO ANTIPROLIFERATIVE ACTIVITY 
 
In vitro antiproliferative activity was assayed as follows. Cells were seeded at 
the initial concentration of 30.000 cells/cm2 and then cultured in the absence or 
in the presence of increasing concentration of plants extracts or purchased 
chemical drugs. The medium was not changed during the induction period. For 
the IC50 (concentrations of extracts leading to 50% inhibition of IB3-1 cell 
growth), we determined the values of cell number/ml after 3 days of culture, 
when untreated cells are in the log phase of cell growth.  
 
7. PREPARATION OF NUCLEAR EXTRACTS 
 
Nuclear extracts were prepared from IB3-1 cells as described [246]. Cell were 
washed twice with PBS and detached by trypsinization. Nuclear proteins were 
obtained by hypotonic lysis, followed by high-salt extraction treatment of nuclei 
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Protein concentration was determined using Bio-Rad protein assay. Nuclear 
extracts were brought to a concentration of 0.5 mg/ml for electrophoretic 
mobility shift assay (EMSA) experiments. 
 
8. ELECTROPHORESIS MOBILITY SHIFT ASSAY (EMSA) 
 
Electrophoresis mobility shift assay (EMSA) was performed by using double-
stranded 32P-labelled oligonucleotides as target DNA [247, 248]. 
Oligodeoxynucleotides were labeled with γ32-P-ATP using 10 Units of T4-
polinucleotidekinase (MBI Fermentas, St. Leon-Rot, Germany) in 500 mM Tris-
HCl, pH 7.6, 100 mM MgCl2, 50 mM DTT, 1 mM spermidine, 1 mM EDTA in the 
presence of 50 mCi γ32-P-ATP) in a volume of 20 µl for 45 minutes at 37°C . 
Reaction was brought to 150 mM NaCl, and 150 ng complementary 
oligodeoxynucleotide was added. Reaction temperature was increased to 
100°C for 5 minutes and left diminishing to room te mperature overnight.  
Binding reactions were set up as described elsewhere in binding buffer (10% 
glycerol, 0.05% NP-40, 10 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.5 mM DTT, 10 
mM MgCl2), in the presence of poly(dI:dC).poly(dI:dC) (Pharmacia, Uppsala, 
Sweden), 2-5 µg of crude nuclear extracts [246] and 0.25 ng of labeled 
oligonucleotide, in a total volume of 20 µl [247, 248]. After 30 minutes of binding 
at room temperature samples were electrophoresed at constant voltage (200 V 
for 1 hr) through a low ionic strength (0.25x TBE buffer) (1x TBE = 0.089 M Tris-
borate, 0.002 M EDTA) on 6% polyacrylamide gels until tracking dye 
(bromophenol blue) reached the end of a 16 cm slab. Gels were dried and 
exposed for autoradiography with intensifying screens at -80°C. In these 
experiments, DNA/protein complexes migrate through the gel with slower 
efficiency.                  
To study inhibition of protein/DNA interactions, addition of the reagents was as 
follows: (a) poly(dI:dC).poly(dI:dC); (b) labelled oligonucleotides mimicking the 
binding sites for transcription factors to be modulated; (c) Saraca asoka,  
Emblica officinalis or Bergamot extracts; (d) binding buffer; (e) nuclear factors. 
62 
 
The nucleotide sequences of double-stranded target DNA utilized in these 
experiments were 5’-CGC FGG GGA CTT TCC ACG G-3’ (sense strand, NF-
kB) (Sigma Genosys, Cambs, UK).              
To study the activation of NF-kB in the inflammatory cascade, we exposed our 
model system of IB3-1 cells to the P. aeruginosa laboratory strain PAO1 
infection: EMSA was perfomed as previously described with double-stranded 
synthetic oligodeoxynucleotides mimicking the NF-kB–binding site present in 
the promoter of the IL-8 gene (IL-8 NF-kB, sense: 5’-AAT CGT GGA ATT TCC 
TCT-3’) incubated with nuclear extracts from IB3-1 cells or purified NF-kB p50 
dimer protein (Promega, Madison, WI) were used at the specified 
concentrations and poly(dI:dC) (1 mg per reaction) was also added to abolish 
nonspecific binding.               
For quantitative determinations, the bands corresponding to protein-DNA 
complexes were analyzed using the BIO-RAD Gel Doc 2000 (Bio-Rad 
Laboratories). The values obtained in the reactions performed in the presence 
of plant extracts or purified NF-kB p50 dimer protein were compared to control 
untreated reactions.  
 
9. QUANTIFICATION OF IL-8 TRANSCRIPTS AND OTHER 
PRO-INFLAMMATORY GENES  
 
Total RNA was isolated (Trizol reagent, Invitrogen), retro transcribed (Reverse 
Transcription System, Promega Corporation, Medison, USA) and the resulting 
cDNA was quantified by relative quantitative real-time PCR [245]. The 
sequences of the oligonucleotides used for amplification of IL-8 mRNA were: 5’-
GTG CAG TTT TGC CAA GGA GT-3’ (forward) and 5’-TTA TGA ATT CTC 
AGC CCT CTT CAA AAA CTT CTC-3’ (reverse); for β-actin mRNA: 5’-TGA 
CGG GGT CAC CCA CAC TGT GCC CAT CTA-3’ (forward); 5’-CTA GAA GCA 
TTT GCG GTG GAC GAT GGA GGG-3’ (reverse). PCR was performed in a 
final volume of 50 µl containing 50 mM KCl, 10 mM TRIS-HCl pH 8.8, 1.5 mM 
MgCl2 by using 1U/reaction of Taq DNA polymerase, 100 µM dNTPs, 0.5 µM 
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PCR primers. The 30 PCR cycles used were as follows: denaturation, 30s, 94 
°C; annealing, 60s, 68 °C; elongation, 60s, 72°C. T he length of the IL-8 PCR 
product was 236 bp [240, 241]. The marker pUC mix 8 (Fermentas, Milan, Italy) 
at 0.5 µg/lane was used.            
For quantitative real-time PCR reaction, 0.5/20 µl aliquots of cDNA were used 
for each Sybr Green real-time PCR reaction to quantify the relative tissue 
expression of IL-8 transcripts and other pro-inflammatory genes. Primer 
sequences and concentration are shown in Table 4. Primer sets were 
purchased from Sigma-Genosys (The Woodlands, TX).  
 
Primer Sequence (5’ to 3’) Accession n° nM 
IL8-F GACCACACTGCGCCAACA AF385628.2 15 
IL8-R GCTCTCTTCCATCAGAAAGTTACATAATTT  15 
GROγ-F CCGGACCCCACTGCG M36821 2.5 
GROγ-R TTCCCATTCTTGAGTGTGGCTA  15 
ICAM1-F TATGGCAACGACTCCTTCTCG NM_000201 15 
ICAM1-R CTCTGCGGTCACACTGACTGA  15 
IP10-F AGTGGCATTCAAGGAGTACCTCTC NM_001565.1 15 
IP10-R GATGCAGGTACAGCGTACGGT  2.5 
RANTES-F CTACACCAGTGGCAAGTGCTC NM_002985.2 15 
RANTES-R TTTCGGGTGACAAAGACGACT  2.5 
MIP1α-F CTACTTTGAGACGAGCAGCCAG NM_002983.1 45 
MIP1α-R GGTTAGGAAGATGACACCGGG  15 
TNFα-F GGACCTCT CTCTAATCAGCCCTC NM_000594 2.5 
TNFα-R TCGAGAAGATGATCTGACTGCC  2.5 
IL1β-F CTCCACCTCCAGGGACAGGA BT007213.1 45 
IL1β-R GGACATGGAGAACACCACTTGTT  15 
IL6-F CGGTACATCCTCGACGGC NM_000600 2.5 
IL6-R CTTGTTACATGTCTCCTTTCTCAGG  45 
 
TABLE 4 – Primers for quantification of gene expression 
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Each 25 µl of total reaction volume contained 0.5 µl of cDNA, 10 pmol of 
primers, 1x iQ™ SYBR® Green Supermix (Bio-Rad Laboratories, Hercules, CA). 
Real-time PCR  reactions were performed for a total of 40 cycles using an 
iCycler IQ® (Bio-Rad Laboratories, Hercules, CA). The relative proportions of 
each template amplified were determined based on the threshold cycle (Tc) 
value for each PCR reaction. The ∆∆Ct method was used to compare gene 
expression data. Each sample was quantified in duplicate from at least two 
independent experiments. Mean ± S.D. values were determined for each fold 
difference. Amplification of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) cDNA served as internal standards (housekeeping gene). Duplicate 
negative controls (no template cDNA) were also run with every experimental 
plate to assess specificity and indicate potential contamination.  
 
10. CYTOKINE PROFILES  
 
Cytokines in tissue culture supernatants released from the cells under analysis, 
were measured by Bio-Plex cytokine assay (Bio-Rad Laboratories, Hercules, 
CA) [249, 250] as described by the manufacturer.          
The Bio-Plex system is a flexible, easy-to-use multiplex analysis system that 
permits the simultaneous analysis of up to 100 different biomolecules (proteins, 
peptides, or nucleic acids) in a single microplate well. By multiplexing with the 
Bio-Plex system, researchers can dramatically increase the amount of useful 
information from rare or volume-limited samples such as cell colture 
supernatants, and decipher complex interrelationships among proteins involved 
in signal transduction pathways. The microplate platform allows the automated 
analysis of 96-well plates with a throughput of more than 1,800 assay points (for 
a 23-plex assay) in 30 minutes.             
The Bio-Plex suspension array is built around three core technologies. The first 
is the family of fluorescently dyed microspheres, or beads, from Luminex Corp. 
The second is a flow cytometer with two lasers and associated optics to 
measure biochemical reactions that occur on the surface of the microspheres, 
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and the third is a high-speed digital signal processor to efficiently manage the 
fluorescent output. These technologies are brought together in the Bio-Plex 
workstation [fig.22].  
 
Figura 22 - (A) 100-Plex LuminexTM; (B) schematic sandwich immunoassay; (C) Red classify 
laser e Green reporter laser; (D) Bio-Plex workstation (BIORAD). 
 
The Bio-Plex suspension array system uses the multiplexing technology of 
Luminex Corp. to enable the simultaneous quantitation of up to 100 analytes. 
This technology uses polystyrene beads internally dyed with differing ratios of 
two spectrally distinct fluorophores. Each fluorophore can have any of 10 
possible levels of fluorescent intensity, thereby creating a family of 100 
spectrally addressed bead sets [fig.22 (A)].       
Bio-Plex assays contain dyed beads conjugated with monoclonal antibodies 
specific for a target protein or peptide such as a cytokine or a phosphoprotein. 
Each of the 100 spectrally addressed bead sets can contain a capture antibody 
specific for a unique target protein. The antibody-conjugated beads are allowed 
to react with sample and a secondary, or detection, antibody in a microplate 
well to form a capture sandwich immunoassay. Multiplex assays can be created 
A
DC
B
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by mixing bead sets with different conjugated antibodies to simultaneously test 
for many analytes in one sample [fig.23].                     
 
 
 
 
FIGURE 23 - Bio-Plex technology 
 
The assay solution is drawn into the Bio-Plex array reader, which illuminates 
and reads the sample. When a red diode "classification" laser (635 nm) in the 
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Bio-Plex array reader illuminates a dyed bead, the bead's fluorescent signature 
identifies it as a member of one of the 100 possible sets. Bio-Plex Manager 
software correlates each bead set to the assay reagent that has been coupled 
to it (for example, an IL-2 capture antibody coupled to bead #36). In this way the 
Bio-Plex system can distinguish between the different assays combined within a 
single microplate well. A green "reporter" laser (532 nm) in the array reader 
simultaneously excites a fluorescent reporter tag (phycoerythrin, or PE) bound 
to the detection antibody in the assay. The amount of green fluorescence is 
proportional to the amount of analyte captured in the immunoassay. 
Extrapolating to a standard curve allows quantitation of each analyte in the 
sample. Patented digital signal-processing algorithms provide simultaneous 
real-time acquisition of classification and reporter signal output from thousands 
of beads per second, supporting up to 100 x 96 = 9,600 analyte measurements 
from each 96-well plate.                 
In our experiments, the custom-made Bio-Plex human cytokine Human 7-Plex 
Panel, which included seven cytokines [IL-1rα, IL-6, IL-8, G-CSF, MCP-1 
(MCAF), RANTES, VEGF] were used. 50 µl of cytokine standards or samples 
(supernatants from treated cells) were incubated with 50 µl of anti-cytokine 
conjugated beads in 96-well filter plates for 30 min at room temperature with 
shaking. Plates were then washed by vacuum filtration three times with 100 µl 
of Bio-Plex wash buffer, 25 µl of diluted detection antibody were added, and 
plates were incubated for 30 min at room temperature with shaking. After three 
filter washes, 50 µl of streptavidin-phycoerythrin was added, and the plates 
were incubated for 10 min at room temperature with shaking. Finally, plates 
were washed by vacuum filtration three times, beads were suspended in Bio-
Plex assay buffer, and samples were analyzed on a Bio-Rad 96-well plate 
reader using the Bio-Plex Suspension Array System and Bio-Plex Manager 
software (Bio-Rad Laboratories, Hercules, CA). 
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11. GC-FID AND GC-MS ANALYSES  
 
The sample extracts were analyzed and the relative peak areas for different 
components weighted by gas chromatography-flame ionization detection (GC-
FID). The relative percentages were determined using GC TRACE 
Thermoquest, equipped with autosampler Triplus Thermo Electron Corporation. 
The column was VF-5ms, 30 m x 0.25 mm. Flow rate was 1.0 mL/min He, and 
split 1:50. Injector temperature, 300 °C; detector temperature, 350 °C. Oven 
temperature was initially 55 °C, raised to 100 °C a t a rate of 1 °C/min, and then 
raised to 250 °C at a rate of 5 °C/min and finally held at that temperature for 15 
min. One µl of each sample (15 mg/mL CH2Cl2) was injected. The percentage 
composition of different components was computed by the normalization 
method from the GC peak areas (data integration software: Jasco-Borwin 
version 1.5, JMBS Developments, Fontaine, France), without correction factors. 
Identification was performed by a Varian GC-3800 gas chromatograph 
equipped with a Varian MS-4000 mass spectrometer with electron impact and 
hooked to a NIST (National Institute of Standards and Technology) library. A 
Varian FactorFour VF-5ms poly-5% phenyl-95%-dimethyl-siloxane bonded 
phase column (i.d., 0.25 mm; length, 30 m; film thickness, 0.15 µm) was used. 
Operating conditions were as follows: injector temperature 300 °C; FID 
temperature 300 °C, Carrier (Helium) flow rate 1.0 mL/min and split ratio 1:50. 
The MS (mass spectrometry) conditions were as follows: ionization voltage, 70 
eV; emission current, 10 µAmp; scan rate, 1 scan/s; mass range, 29-400 Da; 
trap temperature, 150 °C, transfer line temperature , 300 °C. The main 
compounds were identified by comparing their relative retention time, KI (Kovats 
Index) and the MS fragmentation pattern with pure compounds and by matching 
the MS fragmentation patterns with the above mentioned mass spectra libraries 
and with those in the literature [251]. To determine the Kovats index of the 
components, an alkenes mixture (C8–C24) was added to the sample extracts 
before injecting in the GC–MS equipment and analyzed under the same 
conditions as above. 
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12. HPLC ANALYSIS 
 
High-pressure liquid chromatography (HPLC) analysis was performed to 
quantify the main constituents. Therefore, pure commercial standards were 
used as external standards to set up and calculate appropriate calibration 
curves. The experimental conditions were performed using a Jasco modular 
HPLC (Tokyo, Japan, Model PU 2089) coupled to a Diode Array apparatus (MD 
2010 Plus) linked to an injection valve with a 20 µL sampler loop. The column 
used was a Tracer extrasil ODS2 25x0.46 cm, with a flow rate of 1.0 mL/min. 
The mobile phase employed consisted of the solvent solution B (methanol) and 
A (water/ formic acid = 95/5). The gradient system adopted was characterized 
by 4 steps: 1. isocratic, with solvent solution B/A=40/60 (%), for 2 min; 2. the 
solvent solution B raised progressively from 40 to 60% in 18 min (from min 2 to 
min 20) until reaching the ratio B/A=60/40 (%); 3. the solvent solution B then 
raised 100% in 4 min (from min 20 to min 24); 4. the solvent solution ratio 
reached B/A=40/60 in 4 min (from min 24 to min 28). Injection volume, 40.0 µl. 
Chromatograms were recorded and peaks from sample extracts were identified 
by comparing their spectra with spectra obtained with pure standards. Peak 
area was determined by integration using dedicated Borwin software (Borwin 
ver. 1.22, JMBS Developments, Grenoble, France). The qualitative and 
quantitative analysis of each extract was performed 3 times. 
 
13. 1H NMR FINGERPRINTING ANALYSIS 
 
Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Gemini-
400 spectrometer operating at 399.97 MHz and at temperature of 303 K. 
Sample extracts (10 mg) were dissolved in deuterated chloroform (0.8 mL) in a 
5mm NMR tube; solvent signal was used for spectra calibration (1H 7.26 ppm). 
1H spectra were run using a standard pulse sequence “s2pul”. 1H NMR spectra 
in CDCl3 of the main constituents of plant extracts were compared with spectra 
obtained at the Spectral Database for Organic Compounds (SDBS free site 
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organized by National Institute of Advanced Industrial Science and Technology 
-AIST- Japan). 
 
14. STATISTICAL ANALYSIS 
 
Data are presented as the mean ± SEM from at least three independent 
experiments. Statistical analysis was performed by one-way analysis of 
variance followed by the Student's t-test. A P value < 0.005 was considered 
statistically significant. 
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RESULTS 
 
1. INDUCTION OF PRO-INFLAMMATORY GENES 
BY P. AERUGINOSA IN IB3-1 CELLS 
 
Respiratory epithelial cells paving the conductive airways are known to play a 
key role as early sensors of the presence of pathogens by expressing a series 
of soluble molecules aimed at recruiting and activating immune cells. P. 
aeruginosa, a critical pathogen in CF chronic lung pathology, is known to induce 
a proinflammatory response in respiratory epithelial cells. Therefore, we 
exposed the bronchial epithelial cell line IB3-1, which expresses the 
DF508/W1282X-mutated CFTR protein, to the P. aeruginosa laboratory strain 
PAO1 for 4 hours, and total RNA was extracted to quantify transcripts. As 
shown in figure 24, PAO1 induced a very strong up-modulation of (1) IL-8 and 
GRO-γ, which recruit polymorphonuclear neutrophils (PMNs); (2) of ICAM-1, 
which cooperates as an adhesion molecule in driving the migration of 
leukocytes through both endothelial and epithelial monolayers; and (3) of the 
pro-inflammatory cytokines IL-1β and IL-6 in IB3-1 cells. These data confirm the 
role of bronchial epithelial cells in the early induction of pro-inflammatory stimuli 
upon exposure to P. aeruginosa.  
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FIGURE 24 - Effects of P. aeruginosa-dependent cytokine transcription 
on IB3-1 cells. 
 
2. SEARCH FOR TRANSCRIPTION FACTOR 
BINDING SITES WITHIN THE PROMOTERS OF 
PRO- INFLAMMATORY GENES 
 
The P. aeruginosa infection of bronchial epithelial cells is known to induce 
expression of genes of the innate immunity by activating different TFs, such as 
NF-kB, AP-1, Elk-1, and NF–IL-6 [195-197]. To propose a TF decoy approach 
to down-modulate gene expression, the analysis of the promoter sequences of 
the target genes is very important. To this end, we evaluated the presence of 
TF signals within the genes modulated by PAO1 treatment of IB3 cells. The 
analysis reported in figure 25 describes the presence of several sequences that 
are putative targets of transcription factors. Among these sequences, NF-kB 
binding sites are present in all the promoters analyzed. Since NF-kB plays a 
well known pivotal role in inflammatory processes, we choose it as the first 
molecular target for the TF decoy approach. 
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FIGURE 25 - Schematic representation of the position of the consensus sequences of the major 
transcription factors identified in the 59-untranslated regions of IL-8, GROγ, ICAM-1, IL- 
1β and IL-6 genes (35, 44–47). Transcription factor consensus sequences have been 
completed by the free-access TF-search software 
(http://www.cbrc.jp/research/db/TFSEARCH.html). 
The positions of the TATA box and of the consensus sequences identified have been reported 
relatively to the translation start sites of each gene. 
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3. TRANSCRIPTION FACTOR DECOY 
 
3.1  EFFECT OF NF-kB DECOY ODNs ON NUCLEAR 
EXTRACTS 
 
Due to its role in recruiting PMNs in the bronchial wall and lumen of the 
patients, down-modulation of IL-8 is considered a key target to reduce the 
damage of the CF airway tract. Since consensus sequence for the transcription 
factor NF-kB is contained in the promoter of IL-8 gene, the CF bronchial IB3-1 
cells were transfected with TF decoy ODNs that have been previously designed 
to mimic the DNA binding site of NF-kB and tested in their capacity to interfere 
with the NF-kB dependent transcription [235]. A double-stranded ODN 
homologous to the NF-kB binding site present in the LTR of the 
immunodeficiency type I virus (HIV-1 LTR NF-kB decoy ODN) has been 
previously demonstrated by our research group to efficiently interact with NF-kB 
p52 transcription factor [252]. Moreover, a new decoy ODN homologous to the 
NF-kB consensus sequence identified in the promoter of the IL-8 gene (IL-8 NF-
kB decoy ODN) was designed and prepared for this purpose. We exposed our 
model system of cells to the P. aeruginosa laboratory strain PAO1 and studied 
the activation of NF-kB by EMSA. As shown in figure 26-A, P. aeruginosa 
increases NF-kB TF, as expected from previously reported data.         
To test the ability of the decoy ODNs to compete for the binding of NF-kB TF 
with the sequence contained in the promoter of IL-8, all the decoy ODNs were 
incubated with nuclear extracts from IB3-1 cells in the presence of a 
radiolabeled probe 100% homologous with the IL-8 NF-kB sequence, and 
EMSA was performed. Complete inhibition of interaction of the 32P labeled IL-8 
NF-kB probe with NF-kB proteins present in the nuclear extracts (NF-kB:DNA 
complex) was obtained with very low concentrations of the IL-8 NF-kB cold 
probe and both HIV-1 LTR 5 and 10 ng, as shown in figure 26-B. To further 
validate the specificity of the competition, the same ODNs were used in the 
binding experiments of the 32P-labeled IL-8 NF-kB probe with purified TF NF-kB 
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subunits. Pre-incubation of the HIV-1 LTR ODN with purified NF-kB p50 dimer 
completely abolish the binding to the 32P-labeled IL-8 NF-kB probe, as reported  
 
 
FIGURE 26 - Effect of decoy ODNs on molecular interactions between nuclear proteins and the 
32P-labeled IL-8 NF-Kb DNA target molecule. (A) IB3-1 cells (2x106 cells/Petri 
dish) were infected with P. aeruginosa laboratory strain PAO1 (20 cfu/cell) or PAO1 suspension 
medium (not infected) for 2 hours. Nuclear extracts (from 0.5 to 4 
mg) were incubated for 20 minutes in the presence of 32P-labeled IL-8 NF-kB 18-mer probe. 
Protein:DNA complexes were separated by polyacrilamide gel electrophoresis. The 
arrow indicates the protein:DNA complexes. The asterisk indicates the free 32P-labeled 18-mer 
probe; (-) indicates 32P-labeled 18-mer probe without nuclear extracts. (B) Nuclear extracts from 
IB3-1 cells (3 mg) were incubated for 20 minutes in the absence (-) or presence of the indicated 
amounts (5 or 10 ng) of the HIV-1 LTR NF-kB or IL-8 NF-kB cold probe DNA/DNA molecules. 
After this incubation period, a further 20-minute incubation step was performed in the presence 
of 32P-labeled IL-8 NF-kB 18-mer probe. (C) Purified NF-kB p50 dimer protein (10 ng) was 
incubated for 20 minutes in the absence (-) or presence of 100 ng of the HIV-1 LTR NFkB or IL8 
NF-kB cold probe DNA/DNA molecules. 
ng 
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in figure 26-C. Interestingly, the competition of the HIV-1 LTR ODN was even 
more effective than that obtained with the IL-8 NF-kB decoy ODN, with a core 
sequence 100% homologous to the consensus sequence contained in the 
promoter of IL-8, that shows the presence of a residual, albeit very small, 
p50:DNA complex [fig.26-C]. Altogether, these EMSAs provide proof of principle 
of the competition of these NF-kB decoy ODNs for the DNA consensus 
sequence contained in the promoter of the IL-8 gene. 
 
3.2 EFFECT OF NF-kB DECOY ODNs IN IB3-1 CELLS 
 
To test the effect of ODNs on gene transcription, complexes of cationic 
liposomes with NF-kB or scrambled ODNs were pre-incubated with IB3-1 cells 
24 hours before exposure to the PAO1 laboratory strain of P. aeruginosa for a 
further 4 hours. HIV-1 LTR NF-kB decoy ODN strongly inhibited transcription of 
IL-8 mRNA, whereas, as reported in the dose-response experiment shown in 
figure 27-A, the IL-8 NF-kB decoy ODN resulted in a less potent effect with 
respect to bacteria-treated cells, either when compared with untreated or 
scrambled ODN-treated IB3-1 cells. The dose-response experiments reported in 
figures 27-B suggest that the HIV-1 LTR NF-kB exhibits its maximal inhibitory 
effect already at a low concentration. 
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FIGURE 27 - Effect of NF-kB decoy ODNs on P. aeruginosa dependent 
induction of IL-8 mRNA in IB3-1 cells. (A) Cells were pre-incubated for 24 
hours with HIV-1 LTR, IL-8 NF-kB decoys, scrambled ODNs, or medium alone before infection 
with P. aeruginosa, PAO1 strain. Total RNA was extracted 4 hours after infection and IL-8 
mRNA was quantified as described in MATERIALS AND METHODS. (B) Effect of HIV-1 LTR 
NF-kB decoy ODN on IL-8 transcription after infection with PAO1 (100 CFU/cell) for 4 hours. 
Data are mean 6 SEM and are representative of three separate experiments. 
 
Since DNA-binding sequences for the TF NF-kB have been reported also in the 
promoters of the other four genes that we found induced by P. aeruginosa in 
IB3-1 cells, as described in figure 24, the question arose if whether, in addition 
to IL-8, the NF-kB decoy ODNs inhibit the transcription of other pro-
inflammatory genes induced by PAO1. HIV-1 LTR NF-kB decoy ODN did not 
show inhibitory effects on the P. aeruginosa-dependent transcription of GRO-γ, 
ICAM-1, and IL-1β and only minor and not significant effects were observed of 
the expression of IL-6 gene, as shown in figure 28.  
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FIGURE 28 - Effect of NF-kB decoy ODNs on induction of different cytokines. HIV-1 LTR NF-kB 
decoy ODN was tested on transcription of ICAM-1, IL-8, GROγ, IL-1β, and IL-6 genes in (A) 
IB3-1 bronchial cells derived from patients with CF after infection with P. aeruginosa. (B) Effect 
of IL-8 NF-kB ODN decoy on cytokine transcripts induced by infection with P. aeruginosa in IB3-
1 cells. Decoy or scrambled ODNs were pre-incubated with IB3-1 cells for 24 
hours before infection with PAO1 (150 cfu/cell) for 4 hours. Total RNA was extracted and 
processed for quantification of transcripts as described in MATERIALS AND METHODS. Values 
are mean 6 SEM of four separate experiments. Significance in Student’s t test between each 
scrambled and decoy ODNs: *P<0.05 or **P<0.01. 
 
The newly designed IL-8 NF-kB decoy ODN was also tested on the transcription 
of the different genes induced by P. aeruginosa. As shown in figure 28-B, IL-8 
NF-kB decoy ODN inhibits IL-8 transcription induced by P. aeruginosa, although 
with lower efficiency than that observed with HIV-1 LTR NF-kB, together with a 
partial inhibition of P. aeruginosa dependent transcription of GRO-γ and IL-6. 
So far, the main message from these results indicates that newly designed 
decoy ODNs directed against the transcription factor NF-kB can inhibit P. 
aeruginosa dependent transcription of IL-8. Since different NF-kB decoy ODNs 
B 
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have been previously tested in respiratory cells stimulated exposed to the pro-
inflammatory cytokine TNF-α, obtaining a much lower degree of inhibition [236], 
we performed further experiments, exposing IB3-1 cells to either TNF-α and IL-
1β, with the aim to gain preliminary information on whether the difference was 
more likely related to the ODN sequences or the pro-inflammatory challenge 
used. Both pro-inflammatory stimuli induced transcription of the same pattern of 
genes induced by P. aeruginosa, as shown in figures 29-A and 29-B. However, 
when cells were challenged with both stimuli and P. aeruginosa, the most 
effective HIV-1 LTR NF-kB decoy ODN inhibited significantly IL-8 mRNA 
induced by PAO1 and IL- 1β but had a much more limited effect on TNF-α 
dependent transcription of this chemokines, as reported in figure 29-C. 
 
 
FIGURE 29 - Effect of different pro-inflammatory stimuli on transcription of IL-8 mRNA. 
Induction of cytokine transcription by (A) TNF-α (50 ng/ml) and (B) IL-1β (10 ng/ml) in IB3-1 
cells. Cells were seeded, serum starved for 18 hours, and incubated with the different stimuli for 
4 hours. (C) Effect of HIV-1 LTR NF-kB decoy ODN on IL-8 transcription in IB3-1 cells treated 
with different stimuli. Decoy or scrambled ODNs were pre-incubated with IB3-1 cells for 24 
hours before stimulation for 4 hours by IL-1β (50 ng/ml), TNF-α (10 ng/ml), or infection with 
PAO1 (100 CFU/cell) for 4 hours. Total RNA was extracted and processed for quantitation of 
transcripts as described in MATERIALS AND METHODS. Values are mean 6 SEM of three 
separate experiments. Significance in Student’s t test between each scrambled and decoy 
ODNs: *P<0.05 or **P<0.01.  
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4. NATURAL PRODUCTS 
 
4.1  BERGAMOT EXTRACTS 
 
In the laboratory of professor Sacchetti, commercial mature C. bergamia fruits 
belonging to three different stocks from organic farming in southern Italy were 
purchased and manually processed to completely remove the epicarp. The raw 
plant material obtained (150 g for each sample stock) was immediately 
suspended in 600 mL of chloroform and processed for the extractions. The 
suspension was homogenized for 5 min and submitted to sonication in an 
ultrasound bath (Ultrasonik model 104X, Ney Dental Inc.) in the dark at a 
constant temperature of 25 °C. Subsequently, the sa mples were filtered and 
centrifuged for 20 min at 3000 rpm. The residue was re-extracted with 400 mL 
of chloroform following the same procedure previously described. The collected 
chloroform extracts, named Extract 1, were partially reduced in volume with a 
rotavapor and then completely dried under nitrogen flow. The total extraction 
yield was 3.6 ± 0.2%. Aliquots (5 g) of these sample extracts (Extract 1) were 
subjected to fractional distillation at 350-400 Pa and 40°C, as described 
elsewhere [253], to completely remove volatile terpene compounds and partly 
oxygenated chemicals. The sediment obtained at the end of the distillation 
corresponded to the Extract 2 samples with an extraction yield of 40.3 ± 0.8%. 
One gram of samples of Extract 2 was then resuspended in 20 mL of diethyl 
ether, vigorously shaken for 30 min, and centrifuged. The supernatant was 
removed, and the residue, corresponding to Extract 3 samples, was collected, 
dried under nitrogen flow, and weighed (yield = 65.1 ± 1.5%). For all laboratory 
processing care was taken to protect the operations from light and oxidizing 
conditions. 
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4.1.1. EFFECT OF BERGAMOT EXTRACTS ON THE EXPRESSION 
OF IL-8 mRNA IN IB3-1 CELLS FOLLOWING TNF-α TREATMENT  
 
In order to determine effects of bergamot extracts on mRNA accumulation, the 
expression of IL-8 gene was studied by RT-PCR analysis of RNA extracted 
from TNF-α treated IB3-1 cells cultured in the presence of increasing 
concentrations of bergamot extracts for 24 hours. These concentrations have 
been chosen according to IC50 values obtained in IB3-1 cell antiproliferative 
experiments reported in figure 30. As target gene, we have decided to study the 
accumulation of IL-8 mRNA because IL-8 gene (a) is one of the most expressed 
interleukin in IB3-1 cells [241], (b) it is strongly induced following TNF-α 
treatment [241], (c) it is clearly involved in inflammatory processes associated 
with CF [15,16]. 
 
FIGURE 30 - Inhibition of cell proliferation (IC50, µg/ml) of bergamot 
extracts on cell growth of IB3-1 cells. The IC50 
values were obtained from three independent experiments ± SD. 
 
Panel A of figure 31 shows representative results obtained by amplifying RNA 
from untreated IB3-1 cells (triangles), TNF-α treated IB3-1 cells (squares) or 
IB3-1 cells treated with IC50 extract 3 (crosses) using primer specific for IL-8 and 
GAPDH RNA sequences. The GAPDH gene was used as reference gene in 
order to normalized the IL-8 mRNA expression. Clear induction of IL-8 
transcripts following TNF-α treatment is evident. Significant inhibitory effects 
were detected following exposure of TNF-α treated IB3-1 cells to IC50 
concentration of extract 3. Panel B of figure 31 presents the complete set of the 
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results obtained by the real-time quantitative RT-PCR data on the effects of 
bergamot extracts on IL-8 mRNA accumulation with respect to GAPDH 
transcripts. The first set of  results consistently obtained is the strong increase 
of IL-8 mRNA transcript in TNF-α treated IB3-1 cells (average, 34 fold, p < 
0.01). In addition, the results obtained indicate that IL-8 mRNA expression is 
much lower in TNF-α treated IB3-1 cells cultured in the presence of bergamot 
extracts. More in detail, extract 1 and extract 3, even when used at IC25 
concentrations, display high level of inhibition of TNF-α induced IL-8 mRNA 
accumulation. IC50 concentrations are necessary to obtain similar inhibitory 
effects using extract 2. 
 
FIGURE 31 – Effects of bergamot extracts on IL-8 mRNA accumulation. IB3-1 were treated with 
80 ng/ml TNF-α in the presence of increasing concentrations of bergamot extracts for 24 hours, 
RNA was extracted and RT-PCR performed with primers specific for IL-8 and β-actin RNA 
sequences. (A) Representative quantitative RT-PCR analysis. Triangles: RNA from untreated 
IB3-1 cells; squares: TNF-α treated IB3-1 cells; crosses: IB3-1 cells treated with IC50 extract 3. 
(B) Effects of bergamot extracts on IL-8 mRNA accumulation with respect to β-actin transcripts. 
(a): IC25 of extract; (b): IC50 of extract. 
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4.1.2. EFFECT OF BERGAMOT EXTRACTS ON THE EXPRESSION 
OF IL-8 GENES INDUCED IN IB3-1 CELLS FOLLOWING TNF-α 
TREATMENT: A BIO-PLEX ANALYSIS 
 
In consideration of the inhibitory activity on IL-8 mRNA accumulation, Bio-plex 
experiments were performed to verify the possible effects of bergamot extracts 
on the release of this protein. IB3-1 cells were treated with 80 ng/ml of TNF-α 
and increasing amounts (IC25-IC50-IC75) of bergamot extracts. After 24 hours, 
recovered supernatants were analyzed using the Bio-Plex human cytokine IL-8 
single-plex (Bio-Rad). When IB3-1 cells were induced with TNF-α and cultured 
in the presence of bergamot extracts, some important differences in the release 
of IL-8 occurred, as reported in figure 32. As it is evident the TNF-α induced 
release of IL-8 (pg/ml) is strongly reduced using extract 1 and 3 at IC50 
concentrations. The effect was found to be concentration-dependent. The 
results obtained indicate a strong inhibition of release of IL-8 using extracts 3, 
even when it was used at IC25 concentration, while extract 2 showed inhibitory 
activity active only at IC75 concentration. These data suggest that bergamot 
extracts might specifically inhibit the expression of the IL-8 pro-inflammatory 
gene. These data are in agreement with the results obtained using the RT-PCR 
approach [fig.31], and sustain the concept that bergamot extracts are potent 
inhibitors of the TNF-α induced expression of the IL-8 gene in IB3-1 cells. 
 
 FIGURE 32 – Effects of bergamot extracts IL
of TNF-α and increasing amounts (a: IC
recovered supernatants were analyzed using the Bio
Rad). (-): untreated IB3
 
4.1.3. PHYTOCHEMICAL INVESTIGATION
 
In consideration of the biolog
phytochemical investigation of the three bergamot extra
order to obtain a qualitative and quantitative determination of the chemical 
constituents of the extracts, with particular reference to non
chemicals, i.e. coumarins and psoralens. 
Sacchetti who performed the 
Normally bergamot oil, extracted by cold pressing of peels is made up of 93
96% volatile compounds, such as monoterpenes, in particular 25
limonene, and high quantities of oxygenated compounds, such as linalool (2
20%) and linalyl acetate (15
oil (4-7%) consists of nonvolatile compounds as pigments, waxes, and above all 
coumarins (e.g., citropten) and psoralens (e.g., bergapten and bergamottin) 
[fig.33].  
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FIGURE 33 - Molecular structures of bergamottin (5-geranyloxypsoralen, A);  
bergapten (5-methoxypsoralen, B); and citropten (5,7-dimethoxycoumarin, C). 
 
The link between these phytochemical aims and the bioactivity assays targets 
was to determine the role, if any, of the non-volatile fraction, or of their 
constituents individually, with or without the synergic interaction of volatile 
chemicals, in the modulation of IL-8 gene expression in in vitro cell models.   
For the chloroform extract (extract 1 samples), composition was similar to that 
in bergamot essential oil with two significant fractions: (a) monoterpenes and 
their correlated compounds and (b) coumarins and psoralens [255]. The 
extraction procedures followed led to products (extract 2 and extract 3 samples) 
with a progressive decrease of volatile compounds and an increase of the 
nonvolatile fraction (coumarins and psoralens) as determined by 
semiquantitative combined GC-FID and GC-MS analyses [Table 5]. Extract 1 
samples showed linalyl acetate (36.12%), linalool (27.35%), and limonene 
(18.78%) as the main constituents, as for bergamot essential oil, whereas 
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coumarins and psoralens made up 4.64% [Table 1]. Extract 2 samples showed 
an important reduction of linalyl acetate (27.45%) and a dramatic decrease of 
other terpene compounds. Many minority chemicals were not detectable, 
whereas others, such as limonene, showed a reduction of 93.2%. Extract 3 
samples gave an even more noticeable reduction of terpene compounds, with 
linalyl acetate (0.43%), γ-terpinene (0.17%), and β-myrcene (0.53%) as the only 
volatile fraction chemicals, against an increase of coumarins and psoralens of 
45.5 and 95.2% with respect to extract 2 and 3 samples, respectively [table 5].  
 
TABLE 5 - Composition of Bergamot Extracts Determined by GC-MS and 
GC-FID 
 
HPLC analyses to detect and quantify coumarins and psoralens reputed to be 
representative of the nonvolatile fraction and of the bioactivity of bergamot 
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crude drug and derived products [212-218, 255] were performed by doctor Ilaria 
Lampronti, who is acknowledged for her work. This showed a homogeneous 
qualitative profile with respect to the occurrence of citropten, bergamottin, 
bergapten, bergaptol, and 5-geranyloxy-7-methoxycoumarin in all bergamot 
extract samples. A total amount corresponding to 5.83% was found in extract 1 
samples, 37.84% in extract 2 samples, and 89.36% in extract 3 samples [table 
6]. Bergaptol and 5-geranyloxy-7-methoxycoumarin were not detectable in the 
three extracts, whereas the other compounds (citropten, bergamottin, 
bergapten) were always identified. The ratio among the detected chemicals 
changed greatly in the different kinds of samples. In samples of extract 1 
bergamottin and bergapten represented 2.57 and 2.89% respectively, whereas 
citropten was detected in lower concentrations (0.37%). In samples of extract 2 
concentrations of bergamottin, bergapten, and citropten were 9.44, 27.26, and 
1.14%, whereas in samples of extract 3 concentrations were 3.10, 85.75, and 
0.51%, respectively [table 6]. 
EXTRACT CITROPTEN BERGAMOTTIN BERGAPTEN BERGAPTOL 5-GERANYLOXY-7-
METHOXYCOUMARIN 
1 0.37 ± 0.03 2.57±0.08 2.89±0.07 *nd Nd 
2 1.14±0.07 9.44±0.17 27.26±0.59 nd Nd 
3 0.51±0.03 3.10±0.06 85.75±1.18 nd Nd 
  *Nd: not detectable 
Table 6 - Coumarins and Psoralens Percentage (w/w ± SD) in the Bergamot Extracts 
Determined by HPLC Analyses. 
 
1H NMR [fig.34] was performed in the laboratory of professor Saccheti, who is 
acknowledged, on all of the samples belonging to the three different extracts in 
order to have a fingerprint of the bergamot phytocomplexes. NMR can 
potentially perform in a single-step analysis the assessment of all organic 
compounds that constitute a phytocomplex [256 and references cited therein]. 
For the three extracts examined it was possible to detect, through a single NMR 
analysis, the presence of psoralens, coumarins, and monoterpenes. This NMR 
approach allows with good approximation the relative amount of each 
detectable component by comparison of the integrals of typical not overlapped 
 signals assigned to these chemicals to be obtained 
case we considered two allyl protons 
proton on C2 on linalool (5.89 ppm) and linalyl acetate (5.97 ppm), doublet of 
proton onC3 on citropten (7.95 ppm), and doublet of proton near the oxygen on 
the furanic ring of bergapten (7.01 ppm) and bergamottin 
 
FIGURE 34 - 1H NMR spectra of samples belonging to Extract 1 (a),
 
In consideration of the fact that extract 3 was the most active on inhibition of 
TNF-α induced IL-8 mRNA accumulation and IL
cells, we hypothesized that the coumarin/psoralen fractions of the extracts were 
among those responsible for the biological activity. Therefore, the activity
citropten, bergapen and bergamottin was further analyzed.
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4.1.4. EFFECT OF IDENTIFIED COMPOUNDS IN BERGAMOT 
EXTRACTS ON EXPRESSION OF IL-8 GENES IN TNF-α TREATED 
IB3-1 CELLS  
 
In order to determine effects of three principal identified compounds on IL-8 
mRNA accumulation, we analyzed by semi-quantitative RT-PCR the level of IL-
8 mRNA in TNF-α treated IB3-1 cells cultured in the presence of increasing 
concentrations of bergamottin, bergapten, citropten for 24 hours [fig.35]. These 
concentrations were chosen according to IC50 values obtained in IB3-1 cell 
antiproliferative experiments (citropten 235µM ± 38,2 SD, bergapten 155,8 µM ± 
43,6 SD, bergamottin 43,25 µM ± 6,2 SD)       
The preliminary results obtained indicate that IL-8 mRNA expression is lower in 
TNF-α treated IB3-1 cells cultured in the presence of bergapten or citropten at 
IC50 concentrations, while bergamottin does not show inhibitory effects at the 
same concentrations [fig.35-A]. The β-actin mRNA (used as housekeeping 
gene) accumulation does not change following bergamot compunds treatment 
[fig.35-B].  
 
FIGURE 35 - Effects of citropten, bergamottin and bergapten on IL-8 mRNA accumulation: 
semi-quantitative RT-PCR analysis. IB3-1 were treated with TNF-α in the presence of IC25 or 
IC50 concentrations of citropten, bergapten and bergamottin as indicated for 24 hours, RNA was 
extracted and RT-PCR performed with primers specific for IL-8 and β-actin RNA sequences. (-): 
untreated IB3-1 cells; (+):IB3-1 cells treated with TNF-α.   
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On the basis of this first set of results, showing that bergapten and citropten 
exhibit an interesting inhibitory activity on mRNA accumulation, to better 
quantify inhibitory effects of  these two identified compounds, we performed 
real-time quantitative RT-PCR analysis on RNA extracted from IB3-1 cells 
induced with TNF-α and treated with IC25 and IC50 concentrations of citropten or 
bergapten, comparing IL-8 mRNA accumulation with that of the internal controls 
β-actin mRNA. Panel A of figure 36 shows the representative results obtained 
by amplifying RNA from untreated (triangles), TNF-α (squares), citropten 
(diamonds, IC50) and bergapten (crosses, IC50) treated IB3-1 cells using primer 
specific for IL-8 RNA. Clear induction of IL-8 transcripts, following TNF-α 
treatment is evident, but this increase is reduced after treatment with citropten 
or bergapten. Particularly citropten is more efficient than bergapten to decrease 
IL-8 mRNA accumulation. This result is more evident in panel B of figure 36, 
showing a summary of the data obtained by real-time quantitative RT-PCR were 
performed to investigate effects of bergapten and citropten at two different 
concentrations (IC25 and IC50) on IL-8 mRNA accumulation. Significant inhibitory 
effects on IL-8 mRNA expression normalized to β-actin transcripts were 
detected following exposure of TNF-α induced IB3-1 cells to citropten and 
bergapten at IC25 concentrations yet. Moreover, citropten was found to be more 
active than bergapten at the same concentrations. These data are in agreement 
with data obtained by semi-quantitative RT-PCR [fig.35], and confirm the potent 
inhibitory activity of citropten and bergapten on expression of the IL-8 gene in 
IB3-1 cells.                         
The results shown in figure 36-B have been also confirmed using Bioplex 
technology to analyze the release of IL-8 protein (pg/ml) in supernatants 
recovered from TNF-α induced IB3-1 cells treated with citropten and bergapten 
at IC50 and IC25 concentrations. These supernatants were collected before to 
perform the RNA extraction for real time PCR analysis. The results, shown in 
figure 36-C, confirmed the inhibitory activity of citropten and bergapten 
(citropten>bergapten) on expression of IL-8 protein in IB3-1 cell model.  
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FIGURE 36 – Effects of citropten and bergapten on IL-8 gene expression. (A-B): mRNA 
accumulation studied by quantitative RT-PCR analysis; (C) Bio-plex analysis of IL-8 protein 
present in supernatants. (A) representative RT-PCR analysis. triangles: untreated IB3-1 cells; 
squares: TNF-α treated IB3-1 cells; diamonds: IB3-1 cells treated with citropten; crosses: IB3-1 
cells treated with bergapten. (B) Summary of the effects of citropten and bergapten on IL-8 
mRNA accumulation with respect to β-actin transcripts. (C) Bio-plex analysis, using the Bio-Plex 
human cytokine IL-8 single-plex (Bio-Rad). (-): untreated IB3-1 cells; (+):IB3-1 cells treated with 
TNF-α.   
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4.2 EMBLICA OFFICINALIS  
 
The dried fruits of Emblica officinalis were extracted with absolute ethanol and 
the yield was 9.33%. This ethanolic extract of Emblica officinalis was defatted 
with petroleum ether and the defatted extract was successively fractionated with 
different solvent systems on the polarity basis. The solvents were 100% 
dichloromethane, 25% ethylacetate-dichloromethane, 50% 
ethylacetatedichloromethane, 75% ethylacetate-dichloromethane, 100% 
ethylacetate, butanol and acetone and the remaining aqueous portions were 
separated. 
 
4.2.1 GAS CHROMATOGRAPHY-MASS SPECTROMETRY 
ANALYSIS OF THE FRACTIONS OF EMBLICA OFFICINALIS 
EXTRACTS 
 
In order to identify the putative antiproliferative compound present within 
unfractionated extracts and n-butanol fraction from Emblica officinalis, gas 
chromatography-mass spectrometry (GC-MS) analysis was performed by 
doctor Ilaria Lampronti, who is acknowledged. Gas chromatography coupled to 
mass spectrometry allows purification and identification of single components 
from biological extracts. Emblica officinalis extracts and the respective n-butanol 
fraction samples were diluted to a final volume of 1 ml with methanol 
(approximately 1 mg/ml). One µl of each solution was injected into the gas 
chromatograph with an appropriate microsyringe, chromatographed using a 
fused-silica capillary column and analyzed with a quadrupole mass 
spectrometric detector. The resulting chromatograms are shown in figure 37-A 
and C, and demonstrate that in Emblica officinalis extracts 3 peaks with 
different retention times (r.t., 13.4, 20.9, 22.3 min) are present. The mass 
spectrometric analysis [fig.37-B, 37-D, and data not shown] demonstrated that 
these 3 peaks correspond to 3 derivatives: a) pyrogallol (or 1,2,3-benzenetriol); 
b) tetradecahydro-1,4-dimethyl-7- (1- methylethyl)-1-phenantrene 
  
FIGURE 37 - (A, C, E), Ion chromatograms of unfracti
butanol fraction of 
(B, D, F), Mass spectrum of peak 1 of unfractionated 
n-butanol fraction of 
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Emblica officinalis extracts (D) and 
pyrogallol (F). 
 
 
extracts (A), n-
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(B), peak 1 of 
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methyl ester; and c) decahydro-4H-cyclopentacycloocten-4-one respectively, 
identified by using the NIST library (Mass Spectrometry Data Handling System, 
version 1.12, Fisons, Thermo Finnigan, San Jose, CA). In the chromatogram of 
the n-butanol fraction of Emblica officinalis extracts [fig.37-C] we can observe 
only one major peak at 13.3 min (r.t.) corresponding to pyrogallol [fig.37-D], also 
present in Emblica officinalis. The retention time (r.t.) and the fragmentation 
pathways are the same as shown in figure 37-A and B. Moreover, we analyzed 
commercial pyrogallol for comparison with the two peaks found in Emblica 
officinalis extracts and the respective n-butanol fraction samples. The r.t. and 
the fragmentation pathways corresponded perfectly [fig. 37-E and 37-F]. 
Accordingly, we hypothesized that the antiproliferative activity of Emblica 
officinalis extracts was due to pyrogallol. M/z values: a) pyrogallol (Emblica 
officinalis extracts): 80.0, 96.8, 107.9, 125.8, 126.9; pyrogallol (Emblica 
officinalis, n-butanol fraction): 80.0, 96.8, 107.9, 125.8, 126.9; pyrogallol 
(Aldrich): 79.9, 96.9, 107.9, 125.9, 127.0; b) 81.0, 99.0, 121.0, 123.0, 150.0, 
164.0, 186.9, 207.0, 279.2, 306.1, 324.2; c) 95.0, 96.0, 98.0, 123.0, 124.0, 
130.8, 166.0, 195.0, 212.1, 241.1, 279.1. 
 
4.2.2 EFFECTS OF EMBLICA OFFICINALIS EXTRACTS ON IN 
VITRO PROLIFERATION OF IB3-1 CELLS 
 
In order to obtain preliminary information on the biological properties of the 
employed extracts, their effects on cell growth were examined. The extracts 
isolated from Emblica officinalis were first tested on IB3-1 cells. Figure 38 
summarizes the data derived from three independent experiments. IB3-3 cells 
were seeded at the initial concentration of 30.000 cells/cm2 and then cultured in 
the absence or in the presence of 0.05-500 µg/ml of Emblica officinalis extracts 
or purchased pyrogallol. For the IC50 (concentrations of extracts leading to 50% 
inhibition of IB3-1 cell growth), we determined the values of cell number/ml after 
3 days of culture, when untreated cells are in the log phase of cell growth. 
95 
 
 
FIGURE 38 - Inhibition of cell proliferation (IC50, µg/mL or µM) of Emblica officinalis 
extracts and identified compound pyrogallol on cell growth of IB3-1 cells. The IC50 
values were obtained from three independent experiments ± SD. 
 
4.2.3 EFFECT OF EMBLICA OFFICINALIS EXTRACTS ON THE 
EXPRESSION OF PRO-INFLAMMATORY GENES INDUCED IN IB3-1 
CELLS BY TNF-α TREATMENT 
 
To verify the potential anti-inflammatory activity of Emblica officinalis extracts 
and its main constituent pyrogallol, Bio-plex experiments were performed 
evaluating the release of pro-inflammatory cytokines and chemokines on 
supernatant of IB3-1 cell model. Accordingly with the results of proliferation 
activity assays [fig.38], IB3-1 cells were treated with increasing amounts (IC12,5-
IC50) of Emblica officinalis extracts or (IC25-IC50) pyrogallol and with or without 
80 ng/ml of TNF-α. After 24 hours, recovered supernatants were analyzed using 
the Bio-Plex human cytokine 7-plex (Bio-Rad). The results shown in table 7 
demonstrated that since the amount of 50 µg/ml Emblica officinalis is able to 
reduce the release of VEGF (Vascular Endothelial Growth Factor) and IL-8 
proteins, by 20 and 37% respectively. Less relevant is the activity of Emblica 
officinalis on down regulation of IL-12, G-CSF, MCP-1, RANTES e IL-10 gene 
expression. Moreover, pyrogallol seems to down regulate gene transcription of 
G-CSF, RANTES, VEGF, by 44, 73 and 63% respectively, and especially of IL8 
by 51%. 
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SAMPLE G-CSF MCP-1 RANTES VEGF IL-6 IL-8 
Control 14,99 5,59 210,35 12.449,02 505,06 568,54 
Emblica 150 µg/ml 12,84 4,82 240,13 9.747,39 477,29 357,07 
Emblica 50 µg/ml 15,04 6,32 293,95 14.051,81 635,65 410,66 
Pyrogallol 150 µM 8,25 3,74 56,19 4.577,81 1.908,5 279,32 
Pyrogallol 100 µM 11,23 5,27 140,25 6.694,74 1.852,45 285,17 
 
TABLE 7 - Effect of Emblica officinalis extracts on release of cytokines and chemokines. IB3-1 
cells were cultured in the presence of increasing amounts (150 and 50 µg/ml), as indicated, of 
Saraca asoka extracts or pyrogallol (150 and 100 µM) for 24 hours. The release of the indicated 
cytokines and chemokines is reported as pg/ml. 
 
When IB3-1 cells were induced with 80 ng/ml of TNF-α and cultured in the 
presence of increasing amounts Emblica officinalis extracts or pyrogallol (as 
described above) for 24 hours, some important differences in the release of  
cytokines and chemokines occured, which are reported in the table 8. 
           
SAMPLES G-CSF MCP-1 RANTES VEGF IL-6 IL-8 
Control *0.55 OOR < 38,63 649,72 18,13 165,44 
C + (TNF-α) 6,36 79,5 137,1 292,95 220,69 1.713,57 
Emblica 150 µg/ml 3,28 13,09 17,78 170,71 541,76 1.458,25 
Emblica 50 µg/ml 5,81 19,10 42,73 220,47 560,80 2.520,49 
Pyrogallol 150 µM 4,45 70,76 22,58 171,25 248,75 1.158,23 
Pyrogallol 100 µM 2,45 78,90 73,52 24,49 201,81 1.197,79 
          OOR=out of range 
 ٭            = extrapolated value 
TABLE 8 - Effect of Emblica officinalis extracts on TNF-α dependent release of cytokines and 
chemokines. IB3-1 cells were induced with 80 ng/ml of TNF-α and 
cultured in the presence of increasing amounts (150 and 50 µg/ml), as indicated, of 
Saraca asoka extracts or pyrogallol (150 and 100 µM) for 24 hours.The release of the indicated 
cytokines and chemokines is reported as pg/ml. 
97 
 
The positive control of the experiment is represented by IB3-1 cells induced with 
TNF-α without Emblica officinalis extracts or components treatment. As it is 
evident the TNF-α induced release of the cytokines and chemokines of the 
panel. These data suggest that Emblica officinalis extracts inhibit especially the 
expression of MCP-1 (-83%), RANTES (-87%), VEGF (-41%), IL-8 (-14%), and 
the pyrogallol the expression of RANTES genes.      
In consideration of the inhibitory activity on IL-8 release, RT-PCR experiments 
were performed to verify the possible effects of Emblica officinalis extracts on 
the expression of this gene. 
 
4.2.4 EFFECT OF EMBLICA OFFICINALIS EXTRACTS AND 
IDENTIFIED COMPOUND PYROGALLOL ON EXPRESSION OF IL-8 
IN TNF-α TREATED IB3-1 CELLS 
 
In order to determine the effects of Emblica officnalis extracts and pyrogallol on 
mRNA accumulation, the expression of IL-8 gene was analyzed by RT-PCR 
analysis of RNA extracted from TNF-α treated IB3-1 cells cultured in the 
presence of increasing concentration of Emblica officinalis extracts for 24 hours 
[fig.39]. These concentrations were chosen according to IC50 values obtained in 
IB3-1 cell antiproliferative experiments reported in figure 38.        
The preliminary results obtained indicate that IL-8 mRNA expression is lower in 
TNF-α treated IB3-1 cells cultured in the presence of Emblica offcinalis at IC25 
(100µg/ml) concentrations, while pyrogallol does not show inhibitory effects at 
the higher concentrations IC75 (150µM) [fig.39-A]. The β-actin mRNA (used as 
housekeeping gene) accumulation does not change following Emblica officinalis 
and pyrogallol treatment [fig.39-B]. 
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FIGURE 39 - Effects of Emblica officinalis and pyrogallol on IL-8 mRNA accumulation: semi-
quantitative RT-PCR analysis. IB3-1 were treated with TNF-α in the presence of IC25 or IC50 
concentrations of Emblica officinalis and pyrogallol as indicated for 24 hours, RNA was 
extracted and RT-PCR performed with primers specific for IL-8 and β-actin RNA sequences. (-): 
untreated IB3-1 cells; (+):IB3-1 cells treated with TNF-α.  
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4.2.5 IN VITRO EFFECT OF EMBLICA OFFICINALIS EXTRACTS ON 
NF-kB TRANSCRIPTION FACTOR ACTIVITY 
 
The ability of Emblica officinalis extracts to interfere with NF-kB binding to DNA 
was investigated, given that the transcription factor NF-kB plays a critical role in 
regulation of a large number of specific pro-inflammatory genes expression. As 
reported in figure 40, a dose dependent effect was observed, indicating the 
ability of Emblica officinalis extracts to completely inhibit NF-kB interaction with 
its cis element, when used at 100, 50, and 25 µg/reaction. The sensitivity of NF-
kB/DNA interactions to Emblica officinalis extracts was demonstrated to be 
related to the type of plant extracts and not to the extracting buffers, since no 
inhibitory effects were observed (a) with the extracting buffer and (b) other 
extracts from medicinal plants, such as Oroxylum indicum, Cuscuta reflexa, 
Paederia foetida, Hygrophilla auriculata, Ocimum sanctum [data not shown and 
258]. 
 
 
FIGURE 40 - Analysis by electrophoretic mobility shift assay of the effects of Emblica officinalis 
extracts on NF-kB DNA binding activity. Nuclear extracts from the IB3-1 cell line were incubated 
with 32P-labelled oligonucleotides (*) NF-kB 
in the presence of different amounts (100, 50, 25, 12.5, 6, 3, 1.5, 1 µg) of Emblica officinalis 
extracts. Protein/DNA complexes and free probe are indicated by arrows. 
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4.3.1. INDUCTION OF CYTOKINE AND CHEMOKINE RELEASE IN 
IB3-1 CELLS TREATED WITH TNF-α 
 
In order to determine the effects of TNF-α treatment on the release of 
chemokines and cytokines, cystic fibrosis IB3-1 cells were treated with 80 ng/ml 
of TNF-α for 24 hours and the supernatants derived from a same number of 
TNF-α treated IB3-1 cells was analyzed using the Bio-Plex human cytokine 
Human 7-Plex Panel (Bio-Rad). The results obtained are shown in figure 43.  
 
FIGURE 43 - Effect of TNF-α on cytokine and chemokine release in IB3-1 cells. IB3-1 cells 
(50,000/cm2) were seeded and incubated in the absence (white boxes) or in  the presence (grey 
boxes) of 80 ng/ml of TNF-α for 24 hours. Supernatants of same numbers of TNF-α treated IB3-
1 cells were analyzed using the Bio-Plex Human 7-Plex Panel (Bio-Rad). The results are 
presented as pg/ml (upper panel). In the lower panel the data are presented as fold increase of 
cytokine and chemokine release in TNF-α treated cells in respect to untreated IB3-1 cells. 
 
An increase of IL-6, IL-8, G-CSF, MCP-1 and RANTES was appreciable. VEGF 
is secreted at high levels in IB3-1 cells, but its release was not further induced 
by TNF-α. The highest fold induction was observed for MCP-1; the highest 
absolute levels of release (pg/ml) were observed for IL-8. These data are in 
agreement with results showing a close relationship between TNF-α stimulation 
 and IL-8 production by CF epithelial c
because they sustain the concept that TNF
system reproducing a high level of expression of proteins relevant for CF. In 
fact, IL-6, G-CSF, MCP-1 and RANTES
reported in several research papers and reviews [
 
4.3.2. EFFECT OF 
PROLIFERATION OF IB3
 
When IB3-1 cells are treated with increasing concentrations of 
extracts the results shown in figure 4
assessed after 3 days of cell growth. No inhibitory effects were found with up to 
50 µg/ml Saraca asoka extracts. IC
FIGURE 44 - Effect of 
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does not cause significant alteration in the cell growth rate. Accordingly, no 
significant increase in the proportion of trypan-blue excluded cells was observed 
following treatment with either TNF-α (80 ng/ml), Saraca asoka extracts (1, 10 
and 30 µg/ml), or both (not shown). These data demonstrate that TNF-α and 
Saraca asoka extracts are not cytotoxic on IB3-1 cells under the experimental 
condition employed. 
 
4.3.3. EFFECT OF SARACA ASOKA EXTRACTS ON THE 
EXPRESSION OF PRO-INFLAMMATORY GENES INDUCED IN IB3-1 
CELLS BY TNF-α TREATMENT 
 
When IB3-1 cells were induced with 80 ng/ml of TNF-α and cultured in the 
presence of increasing amounts (1, 10 and 30 µg/ml) of Saraca asoka extracts 
for 24 hours, some important differences in the release of cytokines and 
chemokines occured, which are reported in the representative experiment 
shown in figure 45. As it is evident [see also the summary Table included in 
figure 45] the release of some TNF-α induced cytokines/chemokines is strongly 
reduced. The effect was found to be concentration-dependent. The results 
obtained indicate a strong inhibition of release of IL-8, MCP-1 and RANTES. 
Low level of inhibition was on the contrary detected analyzing the release of 
VEGF. No inhibitory effects on IL-6 and G-CSF release were found. These data 
suggest that Saraca asoka extracts might inhibit the expression of pro-
inflammatory genes, the most important of which is IL-8. Considering the cell 
number in each well, in a representative experiment untreated IB3-1 secreted 
an average of 0.16 ± 0.02 pg of IL-8/106 cells/24 hours. This value increased to 
2.8 ± 0.6 when IB3-1 cells were treated with TNF-α, and was found to be 3.0 ± 
0.6, 1.8 ± 0.4 and 0.3 ± 0.15  if the cells were cultured with TNF-α in the 
presence of 1, 10 and 30 µg/ml extracts from Saraca asoka, respectively [the 
summary of the results obtained is included in figure 44]. In consideration of the 
inhibitory activity on IL-8 release, RT-PCR experiments were performed to verify 
the possible effects of Saraca asoka extracts on the expression of this gene. 
 FIGURE 45 - Effect of Saraca asoka 
chemokines. IB3
cultured in the presence of i
Saraca asoka extracts for 24 hours. The release of the indicated cytokines and
chemokines is reported as % of control (TNF
lower-right part of the panel 
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4.3.4. SARACA ASOKA EXTRACTS INHIBIT IL-8 mRNA 
EXPRESSION 
 
In order to determine the effects of Saraca asoka extracts on mRNA 
accumulation, the expression of IL-8 gene was analyzed by RT-PCR analysis of 
RNA extracted from TNF-α treated IB3-1 cells cultured in the presence of 1 and 
10 µg/ml of Saraca asoka extracts. The expression of IL-8 was chosen for the 
following reasons: (a) IL-8 is one of the most expressed interleukin in IB3-1 cells 
[fig.43]; (b) it is strongly induced following TNF-α treatment [fig.43]; (c) it is 
clearly involved in inflammatory processes associated with CF [261,262].  
Interestingly, IL-8 exhibit the highest release also in CF cells infected with 
Pseudomonas aeruginosa [240].            
The results obtained clearly indicate that IL-8 mRNA expression is much lower 
in TNF-α treated IB3-1 cells cultured in the presence of 10 µg/ml Saraca asoka 
extracts. No inhibitory effects were found on IL-8 mRNA accumulation in TNF-α 
treated IB3-1 cells cultured with 1 µg/ml Saraca asoka extracts.          
In figure 46-A the preliminary results are shown obtained by semi-quantitative 
RT-PCR, indicating that (a) IL-8 mRNA expression is induced by TNF-α 
treatment and (b) much lower accumulation of IL-8 mRNA is detectable in RNA 
from TNF-α treated IB3-1 cells cultured in the presence of 10 µg/ml Saraca 
asoka extracts. In order to better quantify the effects of Saraca asoka extracts 
real-time quantitative RT-PCR reactions were also performed, comparing IL-8 
mRNA accumulation with that of the internal controls β-actin and GAPDH 
mRNA sequences. Panel B of figure 46 shows the representative results 
obtained by amplifying RNA from untreated (open symbols) or TNF-α treated 
(closed symbols) IB3-1 cells using primer specific for IL-8 and GAPDH RNA 
sequences as indicated. Clear induction of IL-8 transcripts, and no changes of 
GAPDH mRNA accumulation following TNF-α treatment is evident.      
Significant inhibitory effects were detected following exposure of TNF-α treated 
IB3-1 cells to 10 µg/ml Saraca asoka extracts, while low effects were found with 
1 µg/ml Saraca asoka extracts. These data are in agreement with data obtained 
using the Bioplex approach [fig.45], and sustain the concept that extracts from 
 Saraca asoka are potent inhibitors of the TNF
gene in IB3-1 cells. 
FIGURE 46 - Effect of Saraca asoka 
mRNA accumulation. IB3
the presence of 1 and 10 
quantified by semi quantitative RT
In the upper panel a representative semi quantitative RT
indicates the IL-8 specific PCR generated fragments. In the lower panel the
quantitative analyses of two independent experiments are sh
indicated as % of control TNF
RT-PCR experiments representing amplifications of RNA from untreated (open
symbols) or TNF-α treated (closed symbols) IB3
GAPDH RNA sequences, as indicated. 
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4.3.5. SARACA ASOKA EXTRACTS INHIBIT INTERACTIONS 
BETWEEN NF-kB TRANSCRIPTION FACTOR AND TARGET DNA 
SEQUENCES 
 
In order to determine the effects of Saraca asoka extracts on possible molecular 
targets important for the onset of inflammatory state in CF cells, the possible 
effects on the interactions between the nuclear transcription factor kB (NF-kB) 
and target DNA sequences were analyzed by EMSA. NF-kB is indeed involved 
in the inflammatory state of CF [263-265]. Moreover NF-kB is induced, together 
with IL-8, in Pseudomonas aeruginosa infected CF cells. The results, shown in 
figure 47, clearly demonstrate that increasing amounts of Saraca asoka extracts 
fully suppress the interactions between NF-kB and target DNA elements. 
 
FIGURE 47 - Effect of Saraca asoka extracts on molecular interactions between 
nuclear proteins and 32P-labeled NF-kB DNA target molecules. Protein/DNA 
complexes were separated by polyacrylamide gel electrophoresis. The arrow indicates 
the protein/DNA complexes. * indicates the free 32P-labeled probe. A. Nuclear extracts 
from IB3-1 cells (4 µg) were incubated for 20 min in the absence (-) or presence of the 
indicated amounts of Saraca asoka extracts. After this incubation period, a further 20- 
min incubation step was performed in the presence of 32P-labeled NF-kB HIV-1 DNA 
sequences. 
108 
 
DISCUSSION AND FUTURE PERSPECTIVES  
One of the clinical feature of cystic fibrosis (CF) is a deep inflammatory process, 
which is characterized by production and release of cytokines and chemokines, 
among which interleukin 8 (IL-8) represent one of the most important [109-112]. 
In fact, high levels of  IL-8 are exhibited in CF cells infected with Pseudomonas 
aeruginosa or induced with TNF-α [118]. Accordingly, there is a growing interest 
in developing therapies against CF in order to reduce the excessive 
inflammatory response in the airways [99, 100] of CF patients. In this respect, 
among the inducible transcription factors that control inflammatory gene 
expression, nuclear factor NF-kB plays a central role.       
In this thesis, we investigated on two different strategies with the aim of down-
regulate the pro-inflammatory gene expression interfering with NF-kB activation 
pathway: (a) the transcription factor decoy approach; (b) screening of new 
therapeutic molecules identified in extracts from medicinal plants, such as 
Bergamot, Saraca asoka [259, 260] and Emblica officinalis, since they have 
been reported to exhibit anti-inflammatory activities in several studies [221-229].  
 
1. TRANSCRIPTION FACTOR DECOY 
 
In the past few years, the transcription factor decoy approach has been applied 
to modulate gene expression both in vitro [191, 192] and in vivo [193, 194], 
suggesting that this approach has potential value in non viral gene therapy.      
In this thesis, we applied a TF decoy strategy aimed at down-modulating the 
expression of pro-inflammatory genes in wild-type and CF bronchial epithelial 
cells infected with P. aeruginosa. Transfection of bronchial cells with decoy 
ODNs mimicking the NFkB sequences contained in the HIV-1 LTR or IL-8 
genes clearly inhibited P.aeruginosa–dependent expression of IL-8.                  
A TF decoy strategy to down-modulate IL-8 expression was first proposed by 
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Cooper and colleagues in human monocytes stimulated with IL-1β [235]. In that 
experimental model, transfection of a 10-nucleotide decoy ODN 100% 
homologous to the core sequence of NF-kB identified in IL-8 promoter produced 
an average 60% inhibition of the IL-1β - dependent expression of IL-8 gene. 
Application of TF decoy ODNs has been tried by Griesenbach and coworkers 
with a different 20-nucleotide NFkB decoy ODN in CF tracheal epithelial cells 
stimulated with TNF-α, as they obtained only an average 40% inhibition of IL-8 
secretion [236]. The same decoy ODN was unable to inhibit IL-6 secretion after 
bleomycin-induced pneumonia in murine lungs [237]. How can we reconcile 
these previous results with the highly efficient inhibition of IL-8 expression we 
report in the present thesis? Different decoy ODN sequences have been used 
in our experiments with respect to all the previous studies, which could, by itself, 
explain the discrepancies. In addition, Cooper and colleagues [235] used decoy 
ODNs without flanking regions, which could be more easily degraded by 
nucleases cleaving at the 5’ or 3’ ends of the ODNs, thus reducing their 
effectiveness in competing for active NF-kB. Also, the application of different 
pro-inflammatory stimuli could have impact on the efficiency of the NF-kB decoy 
ODNs, a stimulus that we chose considering this pathogen particularly relevant 
to study anti-inflammatory approaches for CF lung pathology. From this point of 
view, we report here that the HIV-1 LTR NF-kB decoy ODN has a lower potency 
of inhibition when IB3-1 cells have been stimulated with TNF-α instead of IL-1β 
and P. aeruginosa [fig.29-C]. This is in agreement with the weak inhibition that 
Griesenbach and coworkers [236] observed after using the same stimulus. This 
can be partly explained considering that TNF-α activates a panel of receptors, 
adapters, and kinases [266], which is quite different than those induced by P. 
aeruginosa, thus suggesting that transcription factors other than NF-kB could 
have a predominant role. Thus differences in the pro-inflammatory stimuli used 
could have an important role besides that played by the choice of the 
sequences of the decoy ODNs.             
NF-kB proteins comprise a family of transcription factors involved in the control 
of a large number of genes related to cellular growth, developmental processes, 
apoptosis, and immune and inflammatory responses (for synopsis see http:// 
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www.NF-kB.org). As far as our bronchial epithelial model system is concerned, 
we found that P. aeruginosa induces transcription of IL-8, GROγ, ICAM-1 IL-1β, 
and IL-6 genes, all of them containing NF-kB consensus sequences in their 
promoters, as summarized also in figure 25. How can we possibly explain that 
the HIV-1 LTR NF-kB decoy ODN strongly inhibits the P. aeruginosa - 
dependent transcription of IL-8, but not that of the other four genes induced in 
parallel in IB3-1 cells? We initially considered that the consensus sequences for 
NF-kB are not 100% homologous in the genes regulated by this transcription 
factor. Many nucleotide variations could be present, as summarized in the 
general NF-kB consensus usually reported (5’-GGG[A/G]NN[C/T][C/T]CC- 3'), 
which in principle accounts for the possibility of 27 different variants. In our 
specific case, none of the seven NF-kB consensus sequences identified in the 
promoters of the five genes that we found induced by P. aeruginosa are 
perfectly homologous with at least one of the others. Consequently, different 
degrees of homology between the HIV-1 LTR NF-kB decoy ODN and the 
consensus sequences in the promoters can be observed. Thus we 
hypothesized that an important parameter modulating the efficacy the NF-kB 
decoy ODNs in inhibiting transcription of IL-8, GRO-γ, ICAM-1, IL- 1β, and IL-6 
should be the degree of homology between decoy ODN and consensus 
sequences.                   
For instance, the three consensus sequences identified within the promoter of 
ICAM-1 gene present the highest number of mismatches with the HIV-1 LTR 
NF-kB decoy ODN that prompted us to test the effect of new decoy ODNs 
designed with 100% homology. Disappointingly, none of the three ICAM-1 NF-
kB decoy ODNs inhibited P. aeruginosa - dependent ICAM-1 transcription, even 
after transfecting the three decoy ODNs together [data not shown 267]. 
Although this unsuccessful attempt could be related to different parameters 
(e.g., length of the ODN, choice of the 5’- and 3’-flanking nucleotides, 
secondary structure, etc.), overall these negative results seem to basically 
disprove the hypothesis. Second, it should be noted that the HIV-1 LTR NF-kB 
decoy ODN is even more homologous to the consensus sequences reported in 
the GRO-γ and IL-6 than in the IL-8 promoter, whereas we proved the decoy 
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ODN being effective in inhibiting transcription of the latter but not of the former 
genes [fig.28]. Third, the IL-8 NF-kB decoy ODN, which is much more 
homologous than the HIV-1 LTR NF-kB decoy ODN with the consensus 
sequence in the promoter of IL-8, is less efficient in inhibiting IL-8 expression 
than the HIV-1 LTR NF-kB decoy ODN and inhibits partially also the 
transcription of GRO-γ and IL-6. Therefore it becomes apparent that the extent 
of homology between decoy ODN and consensus sequences is important but 
not sufficient to explain all the differences in effectiveness of each NF-kB decoy 
ODN in inhibiting the transcription of the five genes that we observed induced 
by P. aeruginosa in bronchial epithelial cells. Extensive analyses of a large 
series of ODNs mutated in their core consensus and/or flanking regions need 
future investigation to thoroughly answer these questions. A further explanation 
of the different efficiency of NF-kB decoy ODNs could be related to the complex 
interplay of transcription factors in the expression of the different genes of 
interest in the present study. Surface structures of P. aeruginosa, like flagellum 
and pili, interact with different receptors expressed on respiratory epithelial 
cells, leading eventually to activation of transcription factors such as NF-kB, AP-
1, Elk-1, and NF–IL- 6, as already reported [195-197]. Interestingly, all the five 
genes we found induced by P. aeruginosa contain in their promoters one or 
more consensus sequences for NF-kB and some of them also for the 
transcription factors AP-1, NF-IL-6, and Sp-1 [fig.25]. Therefore, we hypothesize 
that the competition of the decoy ODN for the binding of NF-kB to its consensus 
sequence is not sufficient to inhibit drastically GRO-γ, ICAM-1, IL-1β, and IL-6 
transcription also because of the hierarchical roles of AP-1, NF-IL-6, and Sp-1 
in respect to NFkB for the transcription of some of those genes.     
As far as the mechanism of action of the decoy ODNs is concerned, we can 
infer various suggestions. The degree of homology between specific decoy 
ODNs and the consensus sequences for the corresponding TF is important but 
not sufficient to predict the efficiency in inhibiting gene transcription. Efficiency 
of each decoy ODN could depend on the secondary structure and the kind of 
flanking regions of the ODNs, and on the hierarchy of the different TFs in 
regulating expression of specific genes. Thus, from a theoretical point of view, 
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our results strengthen the utility of the TF decoy strategy to provide useful 
insights on the issue of regulation of gene transcription. Conversely, as a 
practical consequence useful to applications in human diseases, decoy ODNs 
appear to present the advantage of a much higher gene specificity than 
previously expected. For instance, one may have anticipated a broad inhibitory 
effect of our NF-kB decoy ODNs on all the five genes containing NF-kB 
consensus sequences, whereas experimental results showed that only IL-8 is 
strongly inhibited with selected decoy ODNs. Considering the therapeutic 
applications of TF decoy ODNs to lung disease of patients with CF and/or to 
other human lung diseases in which the innate immunity is involved, we 
propose here a hint for inhibiting master genes in CF pulmonary pathology. This 
means that novel anti-inflammatory approaches focused on specific target 
genes relevant to specific diseases, without having too broad and undesired 
effects on the innate immune response, could be seriously taken into 
consideration. On the opposite side, knowing the redundancy of this response, 
a disease-oriented intervention should be tailored, focusing on the inhibition of 
the relevant pro-inflammatory genes with complementary TF decoy molecules. 
Different molecular approaches can be investigated to obtain a novel anti-
inflammatory intervention. Strictly single-gene-related inhibitory approaches 
could be devised considering the application of anti-sense and Silencing 
inhibitory RNA (SiRNA) nucleotides. However, due to the redundancy of the 
inflammatory response to P. aeruginosa observed in CF lungs, inhibition of one 
chemokine (e.g., IL-8) could be bypassed by other potent chemoattractants 
(e.g., Gro-γ). A much broader inhibitory approach such as the modulation of the 
receptors for pathogens [268] would present the disadvantage of reducing the 
wide array of genes induced by pathogen-associated molecular patterns that 
are critical to maintain the proper anti-infective defenses against pathogens. In 
terms of receptor blockade, those for chemokines could also be a theoretically 
interesting target [269]. However, since chemokine receptors are expressed on 
circulating immune cells, the systemic delivery of antagonist or competing 
molecules could raise safety concerns. All this considered, TF decoy ODNs 
directed toward NF-kB regulating pro-inflammatory genes transcribed in CF 
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respiratory epithelial cells exposed to P. aeruginosa could present the 
advantage of extending or reducing the range of target genes by changing the 
ODN sequence, as observed also in the results presented here. In the 
perspective of application in the respiratory tract, NF-kB decoy ODNs 
conjugated with novel lipoplexes have been successfully utilized in murine 
lungs, obtaining effective inhibition of endotoxic shock (39). However, we are 
perfectly aware that the delivery of decoy ODNs in the conductive airways still 
requires extensive research and development, in particular to ensure sufficient 
stability in respect to degradation in the biological fluids. Recent progress 
obtained in other and our laboratories with PNA-chimeric TF decoy molecules 
that are significantly more permeable to the plasma membrane and resistant to 
the nucleases contained in serum and other biological fluids [247, 248, 252, 
271-273 ] are rendering closer the possibility of extending the TF decoy strategy 
to in vivo pre-clinical experiments. 
 
2. NATURAL PRODUCTS 
 
• EMBLICA OFFICINALIS AND SARACA ASOKA 
Since extracts from medicinal plants have been reported in literature [275-278] 
to exhibit anti-inflammatory activities, it could be interesting to analyze the basis 
of this activity and the possible applications in biomedicine.             
In this respect Emblica offcinalis and Saraca asoka [231, 233, 279] deserves 
great attention. These medicinal plants have been reported to be useful in 
traditional indian medicine for the treatment of several diseases. Fruits of 
Emblica offcinalis are used for the treatment of a number of diseases, such as 
dyslipidemia and atherosclerosis, as hepatoprotective, antibacterial and anti-
inflammatory agent [221-229]. In many cases, Emblica officinalis has been 
shown to be a potent free radical scavenging agent thereby preventing 
carcinogenesis and mutagenesis [227]. Whereas, Saraca asoka is especially 
relied upon as an astringent to treat excessive uterine bleeding of different 
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origin, but also for regulating the menstrual cycle and, in various complex 
formulas, as a tonic for women.                     
In spite of these promising features, the reports on the biological effects of 
extracts from Emblica officinalis and Saraca asoka are few.           
In this thesis we studied the effects of Emblica officinalis and Saraca asoka 
extracts on TNF-α mediated induction of interleukin and chemokines in cystic 
fibrosis IB3-1 cells, considering that: (a) in cystic fibrosis epithelium high levels 
of interleukin (for instance IL-6) [280, 281] and chemokines (for instance IL-8) 
[261, 262] are found; (b) this effect is thought to be mediated, at least in part, by 
TNF-α [243, 282] and (c) targeting IL-8 is considered of great interest in the 
anti-inflammatory treatment of CF patients [198, 201, 241, 245].            
The first conclusion of the results presented in this thesis is that both Emblica 
offcinalis and Saraca asoka extracts are strong inhibitors of IL-8 expression, 
measured at the mRNA (using semi-quantitative as well as real-time 
quantitative RT-PCR assays) and protein level. This was determined in cystic 
fibrosis IB3-1 cells, either TNF-α-untreated (data not shown), or stimulated with 
TNF-α.                  
To validate these results, cytokines and chemokines in culture supernatants 
released from cystic fibrosis IB3-1 cells treated with TNF-α were measured by 
Bio-Plex cytokine assay. When IB3-1 cells were induced with TNF-α and 
cultured in the presence of Emblica officinalis extracts, some important 
differences in the release of MCP-1 (-83%), RANTES (-87%), VEGF (-41%), IL-
8 (-14%) occurred compare to the control (IB3-1 cells induced with TNF-α 
without plant extracts treatment). Similar effects were found after the treatment 
of induced cells with increasing amount of Saraca asoka extracts: the results 
show a down-regulation in MCP-1, RANTES, VEGF and IL-8 expression, by 
92%, 99%, 54% and 96% respectively. These data suggest that Emblica 
offcinalis and Saraca asoka extracts might inhibit the expression of the IL-8 pro-
inflammatory gene. These data are in agreement with the results obtained using 
the RT-PCR experiments, and sustain the concept that these extracts could be 
inhibitors of the TNF-α induced expression of the IL-8 gene in IB3-1 cells.       
All these factors are important in the onset of the inflammatory state in CF 
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patients.               
With respect to the anti-inflammatory activity of Emblica officinalis extracts, the 
identification of bioactive compounds is of interest to restrict biopharmaceutical 
drug design to single or few compounds. Gas chromatography-mass 
spectrometry (GC-MS) analyses showed pyrogallol as the common compound 
present both in unfractionated and n-butanol fraction of Emblica officinalis 
extracts. The Bio-plex analysis on supernatant from TNF-α induced IB3-1 cells 
suggest that pyrogallol inhibits especially the expression of RANTES (-83%) 
gene, but no significant data were obtained on regulation of IL-8 expression. 
These results were confirmed by RT-PCR analysis of RNA extracted from TNF-
α treated IB3-1 cells cultured in the presence of increasing concentration of 
pyrogallol: IL-8 mRNA expression does not show inhibitory effects at the higher 
pyrogallol concentrations.                
The data obtained indicate that Emblica offcinalis and Saraca asoka  extracts 
inhibit NF-kB/DNA interactions. Nevertheless it is not clear the mechanism of 
action of Emblica officinalis and Saraca asoka extracts although an attempt was 
made to determine whether the plant extracts retain an inhibitory activity on the 
transcription factor NF-kB, which is critical for IL-8 gene expression and 
involved in CF inflammation. Phytochemical analysis will be performed to 
understand the main contituents of the extracts in order to evaluate which 
molecules are responsible for the downregulation on IL-8 expression.      
Further experiments to determine other biochemical targets of Saraca asoka 
and Emblica offcinalis extracts and the inhibitory effects on IL-8 gene 
expression in other cellular pathological systems and murine models are 
needed.                                   
 
• BERGAMOT 
The major result of this thesis is the finding that extracts obtained from 
bergamot (Citrus bergamia Risso) epicarps, contain components displaying an 
inhibitory activity on IL-8. This effect has been confirmed both at the mRNA 
116 
 
levels and the protein release in the CF cellular model IB3-1, induced with TNF-
α and treated with low concentrations of bergamot extracts. The qualitative and 
quantitative determination of the chemical constituents of the extracts, with 
particular reference to non-volatile fraction chemicals, has demonstrated the 
presence of citropten, bergamottin and bergapten in all bergamot extract 
samples and with different amounts (%w/w) [table 5 and 6]. In particular the 
coumarin/psoralen portion was the major constituent of the most active among 
the extracts (extracts 3). Accordingly, we hypothesized that the 
coumarin/psoralen portion of these extracts were among the biological active 
components. On the other hand, the data reported do not clarify why extract 2 
exhibited the lower biological activity. It should be noted that the composition of 
extract 1 and extracts 2 is complex and, therefore, the presence of compounds 
exhibiting opposite activity or interfering with the coumarin/psoralen compounds 
cannot be excluded. A second achievement of the results here presented is the 
demonstration that, among the preminent coumarin/psoralen compounds, 
bergapten and citropten were the most active molecules to reduce mRNA level 
of IL-8 in TNF-α treated IB3-1 cells at IC50 concentrations, while bergamottin did 
not show inhibitory effects at the same [fig.35] and at higher doses (data not 
shown). These results have been confirmed by  real-time quantitative RT-PCR 
and Bio-plex analyses. In particular citropten is more efficient than bergapten in 
decreasing IL-8 mRNA/protein accumulation in IB3-1 cells.     
These results clearly indicate that bergapten and citropten are strong inhibitors 
of IL-8 expression and could be proposed as potential anti-inflammatory 
molecules to reduce lung inflammation in CF patients. Further experiments are 
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required to determine: (a) other biochemical targets of citropten and bergapten 
as well as whether the inhibitory effects on IL-8 gene expression are 
reproducible in other cellular pathological systems in which this chemokine 
plays a role; (b) safety, potential toxicity, in vivo bioavailability, stability and 
whether suitable concentrations can be reached following in vivo administration. 
Moreover, it should be considered that coumarin compounds, as reported in 
literature, display anti-proteinase activity [274]. For example, serin proteinase is 
capable to degradate the matrix proteins and is involved in several inflammatory 
respiratory diseases as CF. It could interesting to investigate and correlate the 
anti-inflammatory effect of bergapten and citropten with their possible anti-
proteinase activity. This double role of these comppunds could be useful for the 
treatment of lung inflammation in CF patients.         
Last but not least, it would be of interest to see whether  the effect of bergamot 
and its extracts could play the same role with different inflammation stimuli, 
such as IL-1β or PAO-1. 
 
 
 
 
 
 
 
 
